The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (FMTs) (3rd Edition), 2019-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    January 2020

  • Pages
    641

  • View Count
    5833

Example Insights

The Human Microbiome Market Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030-Context The Human Microbiome Market Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030-Example Highlight The Human Microbiome Market Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030-Development Pipeline The Human Microbiome Market Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030-Stages of development
The Human Microbiome Market Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030-Therapeutic Areas 	The Human Microbiome Market Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030-Different sample types The Human Microbiome Market Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030-Fecal microbiota therapies The Human Microbiome Market Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030-Start-up health indexing
The Human Microbiome Market Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030-Heat map Analysis The Human Microbiome Market Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030-Case Study Human-Microbiome-Market -Overall-Microbiome-market The Human Microbiome Market Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030-Futuer Forecast

 

Overview

The human body is known to harbor numerous communities of microbes, including both beneficial and harmful species, which are collectively referred to as the microbiota. Likewise, the ecological system of commensal, symbiotic, and perhaps pathogenic microorganisms that reside within a host system is called the microbiome.  Research insights, generated primarily  from the Human Microbiome Project (2009) and other independent studies, have demonstrated that an imbalance in the microbiome (also known as dysbiosis) may lead to the development of several chronic clinical conditions, including Clostridium difficile infections (CDIs), irritable bowel syndrome (IBS), diabetes, Crohn’s disease and ulcerative colitis.  Given the role of the microbiota in both disease development and pathogenesis, the concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. The growing popularity and interest in the therapeutic potential of the microbiome is evident across scientific literature; commonly cited terms in this context include microbiome, microflora, microbiota, fecal microbiota therapy (FMT), microbiome diagnostics, or human microbiome, as observed on the NCBI’s PubMed portal, over the last three years. 

Over time, the efforts of industry stakeholders and clinical researchers in this domain have led to the discovery of novel therapeutic strategies, including the establishment of a gut-brain axis, involving the human microbiome. Despite the evident increase in interest (of therapy developers and investors alike) in this field of research, there are currently no approved microbiome-based drugs / therapy products available in the market. However, there is a FMT in the market that is designed to modulate the microbial population within the gut for the treatment of recurrent CDIs. This treatment has been shown to be particularly beneficial to those who are non-responsive to standard-of-care therapies. In addition, a number of microbiome diagnostic tests are available for the detection of digestive and gastrointestinal disorders, inflammatory diseases and certain oncological indications. Further, several technology developers have started using next-generation sequencing techniques and other versatile bioinformatics tools for the characterization of important species of gut microflora. It is also worth mentioning that, in the last 4-5 years, there has been a marked rise in the number of new entrants in this field. Interestingly, several big pharma players have also become actively involved in this domain. Given the fact that there are several candidate therapies in late phases of clinical development, the microbiome-based medical products market can be expected to witness substantial growth over the coming decade.

Scope of the Report

‘The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of microbiome-based medical products (including therapeutics, diagnostics and FMTs), over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, location of headquarters and company size), clinical study sponsor(s) or collaborators, phase of development (clinical, preclinical, and discovery stage) of product candidates, type of molecule (small molecule and biologic), type of therapy (prebiotic, probiotic, and prescription drug), target indication(s), key therapeutic area(s), molecular / biological target (if available), mechanism of action (if available), route of administration, type of drug formulation (tablet, capsule, gel, lotion, cream, ointment, nasal spray and 4+ categories), dosing frequency (reported for clinical candidates only), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of microbiome therapeutics.
  • Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics (which are presently in both preclinical and clinical stages of development); each profile features a brief overview of the company, its financial information (if available), microbiome-based product portfolio, information on advanced stage (phase II and above) pipeline candidates (featuring a drug overview, current status of development, clinical trial information, and clinical trial end-point analysis) and an informed future outlook. 
  • A discussion on the various types of diagnostic tests, specifically highlighting the importance of next-generation sequencing within this field of research, along with [A] a detailed review of the current market landscape of microbiome diagnostic tests, including the information on the developer(s) (such as year of establishment, location of headquarters and company size), stage of development (commercialized and under development), type of sample used (blood, feces, saliva and vaginal swab), target indication(s), key therapeutic area(s), result turnaround time, and purpose of diagnosis, [B] brief profiles of popular diagnostic developers, and [C] an indicative list of screening and profiling test kits, including information on the developer(s) (such as year of establishment, location of headquarters and company size), type of sample used (blood, feces, saliva and vaginal swab), key therapeutic area(s), and result turnaround time.
  • A review of the historical evolution and other relevant aspects of FMT therapies, including details on the process of donor selection, therapy procedure, route of administration, important clinical guidelines, regulatory guidelines and insurance coverage, along with [A] a detailed assessment of the current market landscape of FMT therapies, providing information on FMT developer(s) (such as year of establishment, location of headquarters and company size), status of development (commercialized, clinical, and preclinical stage), target indication(s), key therapeutic area(s), and route of administration, [B] a geographical clinical trial analysis of ongoing / planned / completed studies of FMTs sponsored by non-industry players, featuring details related to specific FMT therapies and analysis based on relevant parameters, such as the number of registered trials, year of registration, current status, phase of development, study design, type of sponsor(s), target indication(s), key therapeutic area(s), key focus areas, number of patients enrolled and leading non-industry player(s), and [C] information on various stool banks (including year of establishment and location of headquarters), along with brief profiles of the most prominent stool banks located across the globe.  
  • A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework, highlighting the current market attractiveness and existing competition across the most popular disease indication(s) for which microbiome therapeutics are under investigation.
  • An analysis of the varied microbiome-focused initiatives of big pharma players (out of top 20 established pharmaceutical players), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome product developers), along with information on funding, partnership activity,  and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation of the individual competitiveness of the initiatives of big pharma players based on multiple relevant parameters.
  • An analysis of the start-ups / small-sized players (established in the last seven years, with less than 50 employees) engaged in the development of microbiome therapeutics and diagnostics, featuring heat map representation based on parameters, such as number of microbiome therapeutics under development, diversity of product portfolio, funding information (including funding amount, number of investors and evolution of investment activity), partnership activity, disease indication(s) being treated and focus therapeutic area(s), and strength of intellectual property portfolio.
  • An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs that are being developed against them, highlighting key epidemiological facts about specific diseases, available methods of diagnosis, and currently available treatment options and their side effects.
  • An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in start-ups / small-sized companies (established in last seven years, with less than 50 employees) that are focused on developing microbiome therapeutics and diagnostics.
  • An elaborate discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, along with [A] an indicative list of contract manufacturers, along with details on year of establishment, location of headquarters, company size, scale of operation, facility location and microbiome production capacity, [B] an indicative list of companies with in-house manufacturing facilities for microbiome therapeutics, along with details on year of establishment, location of headquarters, and company size, [C] an indicative list of CROs that currently claim to have the necessary capabilities to offer various research services (such as screening, sequencing, characterization, analytical), along with details on year of establishment, location of headquarters, company size, and service portfolio details, and [D] an insightful Harvey ball analysis of key considerations that need to be taken into account by industry stakeholders while selecting a suitable CMO / CRO partner.
  • An assessment of the emerging role of big data, highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from microbiome research along with [A] an insightful google trends analysis to demonstrate the rising interest of stakeholders in using big data tools to support microbiome research over the past decade, [B] a list of companies offering big data-related services / tools to support microbiome research, and [C] brief profiles of some of the popular companies that are engaged in this field of research.
  • An informative case study on the various other applications of microbiome products, such as agriculture, animal health, plant health, food products, featuring a list of nearly 80 products, including probiotic supplements, cosmetics, and over-the-counter (OTC) products that are being used as dietary supplements.

One of the key objectives of the report was to estimate the existing market size and identify the future opportunity for microbiome therapeutics, diagnostics and FMTs, over the next decade. The research, analyses and insights presented in this report are based on revenue generation trends based on the sales of approved / late stage (estimated) microbiome therapeutics, diagnostic products and FMTs. The report also features the likely distribution of the current and forecasted opportunity within microbiome therapeutics market across [A] type of therapy (prescription drugs, prebiotics, and probiotics), [B] type of molecule (small molecules and biologics), [C] target indication (acne vulgaris, atopic dermatitis, CDI, Crohn’s disease, diabetes, irritable bowel syndrome, lactose intolerance, nonalcoholic steatohepatitis (NASH), ulcerative colitis, and 5+ categories), [D] therapeutic area (autoimmune disorders, dental disorders, digestive and gastrointestinal disorders, dermatological disorders, infectious diseases, metabolic disorders, oncology, and others), [E] key geographical regions (North America, Europe, Asia-Pacific and rest of the world), [F] leading drug developers, and [G] leading therapeutic products. In addition, it also features the likely distribution of the current and forecasted opportunity within microbiome diagnostics market across [A] target indication (Crohn’s disease, colorectal cancer, diabetes, irritable bowel syndrome, lung cancer, NASH, obesity, and ulcerative colitis), [B] therapeutic area (digestive and gastrointestinal disorders, metabolic disorders and oncology), and [C] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for the uncertainties associated with the growth of microbiome market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 
    
The opinions and insights presented in this study were also influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company / organization names):

  • Lee Jones (President and Chief Executive Officer, Rebiotix)
  • Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic)
  • Colleen Cutcliffe (Co-founder and Chief Executive Officer, Whole Biome)
  • Nikole E Kimes (Co-founder and Vice President, Siolta Therapeutics)
  • James Burges (Executive Director, OpenBiome)
  • JP Benya (Vice President, Business Development, Assembly Biosciences)
  • Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories)
  • Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics) 
  • Mark Heiman (Chief Scientific Officer and Vice President, Research, MicroBiome Therapeutics) 
  • Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies)
  • Assaf Oron (Chief Business Officer, BiomX)
  • Pierre-Alain Bandinelli (Chief Business Officer, Da Volterra)
  • Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical)
  • Aaron Wright (Senior Scientist, Pacific Northwest National Laboratories)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
 

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state and likely evolution of microbiome therapeutics, diagnostics and FMT therapies market in the short-mid term and long term.

Chapter 3 is an introductory chapter that highlights important concepts related to the human microbiome, including a discussion on the role of resident microorganisms in disease development (particularly for conditions caused by an imbalance in the microbiome) and in certain cases, prevention. It presents an elaborate discussion on various functions of the microbiota, emphasizing on the key aspects of the Human Microbiome Project (HMP). Further, the chapter describes the various types of microbiome therapeutics, such as probiotics and prebiotic drugs, which are available / under development. It also provides an overview of the regulatory requirements for live biotherapeutic products (LBPs), in addition to highlighting the challenges associated with the development of microbiome therapeutics.

Chapter 4 includes information on 260 microbiome therapeutics that are currently being evaluated in different stages of development (both clinical and preclinical / discovery). It features a comprehensive analysis of pipeline molecules based on their phases of development (clinical, preclinical, and discovery stage), type of molecule (small molecule and biologic), type of therapy (prebiotic, probiotic, and prescription drug), target indication(s), key therapeutic area(s), molecular / biological target (if available), mechanism of action (if available), route of administration, type of drug formulation (tablet, capsule, gel, lotion, cream, ointment, nasal spray and 4+ categories), dosing frequency (reported for clinical candidates only), and information on special drug designation (if any). Further, the chapter provides information on drug developer(s), highlighting their year of establishment, location of headquarters and company size. It also highlights the various microbiome therapeutics that have been discontinued over the last few years. In addition, the chapter highlights the various technology platforms that are being actively used for the development of microbiome therapeutics.

Chapter 5 features detailed profiles of key players (established after 2005) that are engaged in the development of three or more microbiome therapeutics in both preclinical and clinical stages of development, with at least one candidate in the late stages of development (phase II and above). Each profile features a brief overview of the company, its financial information (if available), microbiome-based product portfolio, information on advanced stage (phase II and above) pipeline candidates (featuring a drug overview, current status of development, clinical trial information, and clinical trial end-point analysis) and an informed future outlook. 

Chapter 6 features a discussion on the various types of diagnostic tests, specifically highlighting the importance of next-generation sequencing within this field of research. Further, it includes information on over 30 microbiome diagnostic tests that are currently available / under development, along with information on the developer(s) (such as year of establishment, location of headquarters and company size), stage of development (commercialized and under development), type of sample used (blood, feces, saliva and vaginal swab), target indication(s), key therapeutic area(s), result turnaround time, and purpose of diagnosis. It also includes brief profiles of the popular diagnostic developers that are engaged in the development of four or more diagnostic tests. Additionally, it includes an indicative list of screening and profiling test kits, including information on the developer(s) (such as year of establishment, location of headquarters and company size), type of sample used (blood, feces, saliva and vaginal swab), key therapeutic area(s), and result turnaround time.

Chapter 7 presents an elaborate discussion on the historical evolution and other relevant aspects of FMT therapies, including details on the process of donor selection, procedure, route of administration, clinical guidelines, regulatory guidelines and insurance coverage. Further, it highlights the present scenario of FMT therapies, along with [A] a detailed assessment of the current market landscape of FMT therapies, providing information on industry developer(s) (such as year of establishment, location of headquarters and company size), status of development (commercialized, clinical, and preclinical stage), target indication(s), key therapeutic area(s), and route of administration, [B] a geographical clinical trial analysis of ongoing / planned / completed studies of FMTs sponsored by non-industry players, featuring details related to specific FMT therapies and analysis based on relevant parameters, such as the number of registered trials, year of registration, current status, phase of development, study design, type of sponsor(s), target indication(s), key therapeutic area(s), key focus areas, number of patients enrolled and leading non-industry player(s), and [C] information on the various stool banks (including year of establishment and location of headquarters), along with brief profiles of the most prominent stool banks located across the globe. 

Chapter 8 features an insightful analysis of top indications, across various therapeutic areas under investigation, based on the 9-box AC matrix framework. It further includes a discussion on the relative market attractiveness and existing competition across the most popular disease indication(s). The purpose of the analysis is to enable companies to analyze their product portfolio, develop informed growth strategies (with regard to indications), and also make decisions related to developing products for the top indications.

Chapter 9 highlights the efforts of the top 11 big pharma players engaged in the field of microbiome therapeutics and diagnostics. It features a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome product developers), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation of the individual competitiveness of the initiatives of big pharma players based on multiple relevant parameters.

Chapter 10 presents the detailed analysis of start-ups / small-sized players (established in the last seven years, with less than 50 employees) engaged in the development of microbiome therapeutics and diagnostics. It includes a heat map analysis based on parameters, such as number of microbiome therapeutics under development, diversity of product portfolio, funding information (including funding amount, number of investors and evolution of investment activity), partnership activity, disease indication(s) being treated and focus therapeutic area(s), and strength of intellectual property portfolio.

Chapter 11 presents an elaborate discussion on the most commonly targeted therapeutic indications and brief descriptions of the microbiome-based drugs that are being developed against them. It highlights the key epidemiological facts about the specific diseases, available methods of diagnosis, and currently available treatment options and their side effects.

Chapter 12 presents details on various investments received by start-ups / small-sized companies (established in the last seven years, with less than 50 employees) that are focused on developing microbiome therapeutics and diagnostics. It also includes an analysis of the funding instances that have taken place in the market, up to 2019 (till October), highlighting the growing interest of the venture capital (VC) community and other strategic investors within this domain.

Chapter 13 feature an elaborate discussion on the various steps involved in the development and manufacturing of microbiome therapeutics. Further, the chapter includes [A] an indicative list of contract manufacturers, along with details on year of establishment, location of headquarters, company size, scale of operation, facility location and microbiome production capacity, [B] an indicative list of companies with in-house manufacturing facilities for microbiome therapeutics, along with details on their year of establishment, location of headquarters, company size, and [C] an indicative list of CROs that currently claim to have the necessary capabilities to offer various research services (such as screening, sequencing, characterization, analytical), along with details on year of establishment, location of headquarters, company size, and service portfolio details. Additionally, it includes an insightful Harvey ball analysis of key considerations that need to be assessed by industry stakeholders while selecting a suitable CMO / CRO partner.

Chapter 14 presents an assessment of the emerging role of big data, highlighting the development and implementation of various algorithms / tools to analyze data generated from microbiome research, in order to understand the relationship between the microbiome and the host. Further, it features [A] an insightful google trends analysis to demonstrate the rising interest of stakeholders in using big data tools to support microbiome research over the past decade, [B] a list of companies offering big data-related services / tools to support microbiome research, and [C] brief profiles of some of the popular companies that are engaged in this field of research.

Chapter 15 features an elaborate market forecast analysis, highlighting the future potential of microbiome therapeutics till 2030. Based on an informed top-down approach, taking into account current and projected performance of the microbiome therapeutics market, it features the likely distribution of the current and forecasted opportunity across [A] type of therapy (prescription drugs, prebiotics, and probiotics), [B] type of molecule (small molecules and biologics), [C] target indication (acne vulgaris, atopic dermatitis, CDI, Crohn’s disease, diabetes, irritable bowel syndrome, lactose intolerance, NASH, ulcerative colitis, and 5+ categories), [D] therapeutic area (autoimmune disorders, dental disorders, digestive and gastrointestinal disorders, dermatological disorders, infectious diseases, metabolic disorders, oncology, and others), [E] key geographical regions (North America, Europe, Asia-Pacific and rest of the world), [F] leading drug developers, and [G] leading therapeutic products. The potential sales forecast of the therapeutic products that are in late stages of development (phase III and above) is based on multiple relevant parameters, such as target consumer segments, region-specific disease prevalence, anticipated adoption of the late stage drugs and likely selling price. 

Chapter 16 features a detailed market forecast analysis, highlighting the future potential of microbiome-based diagnostic tests till 2030. Based on multiple parameters, such as target consumer segments, disease prevalence, anticipated adoption of diagnostic tests and price, the analysis provides an informed opinion on the likely distribution of the current and forecasted opportunity across [A] target indication (Crohn’s disease, colorectal cancer, diabetes, irritable bowel syndrome, lung cancer, NASH, obesity, and ulcerative colitis), [B] therapeutic area (digestive and gastrointestinal disorders, metabolic disorders and oncology), and [C] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). It is worth mentioning that a bottom-up approach was adopted for this analysis, wherein our estimates of the likely size of the microbiome-based diagnostics market were validated using relevant datapoints and inputs from primary research. The chapter features market projections both in terms of value (USD million) and volume (number of diagnostic tests). 

Chapter 17 features an informed market forecast analysis, highlighting the future opportunity within the FMT therapies market till 2030, based on parameters, such as the average number of FMT procedures conducted in a year and average cost of approved FMT therapies. It is worth mentioning that the chapter features market projections both in terms of value (USD million) and volume (number of procedures). 

Chapter 18 is a case study focused on the other applications of microbiome products, such as in the field of agriculture, animal health, plant health, and food products. It also features a list of nearly 80 microbiome products, including probiotic supplements, medical food products, cosmetics, and OTC products, which are being used as dietary supplements.

Chapter 19 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 20 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Lee Jones (President and Chief Executive Officer, Rebiotix), Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic), Colleen Cutcliffe (Co-founder and Chief Executive Officer, Whole Biome), Nikole E Kimes (Co-founder and Vice President, Siolta Therapeutics), James Burges (Executive Director, OpenBiome), JP Benya (Vice President, Business Development, Assembly Biosciences), Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories), Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics), Mark Heiman (Chief Scientific Officer and Vice President, Research, MicroBiome Therapeutics), Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies), Assaf Oron (Chief Business Officer, BiomX), Pierre-Alain Bandinelli (Chief Business Officer, Da Volterra), Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical), and Aaron Wright (Senior Scientist, Pacific Northwest National Laboratories)

Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 22 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of Microbiota and Microbiome
3.2.1. Discovery of the Human Microbiome
3.2.2. Functions of the Human Microbiome

3.3. Overview of Gut Flora
3.3.1. Role of Gut Flora in Healthy Individuals
3.3.2. Factors Affecting Gut Flora
3.3.2.1. Antibiotic Consumption
3.3.2.2. Age and Pregnancy
3.3.2.2.1. Mode of Childbirth
3.3.2.2.2. Type of Feeding
3.3.2.2.3. Antibiotic Consumption by Mother
3.3.2.3. Stress-related Factors
3.3.2.4. Dietary Factors
3.3.2.5. Impact of Lifestyle

3.4. The Microbiome and Disease
3.4.1. Cancer
3.4.2. Inflammatory Bowel Disease (IBD)
3.4.3. Obesity
3.4.4. Parkinson’s Disease
3.4.5. Type-II Diabetes
3.4.6. Other Disease Indications
3.5. Impact of Microbiota on Drug Pharmacokinetics
3.6. Impact of Microbiota on Therapeutic Outcomes

3.7. Microbiome Therapeutics
3.7.1. Probiotics
3.7.1.1. Beneficial Bacterial Strains
3.7.1.1.1. Lactobacilli
3.7.1.1.2. Bifidobacteria
3.7.1.1.3. Others

3.7.1.2. Key Therapeutic Areas
3.7.1.2.1. Antibiotic-Associated Diarrhea (AAD)
3.7.1.2.2. Bacterial Vaginosis
3.7.1.2.3. High Blood Pressure
3.7.1.2.4. Hypercholesterolemia
3.7.1.2.5. Infectious Childhood Diarrhea (ICD)
3.7.1.2.6. Inflammatory Bowel Disease (IBD)
3.7.1.2.7. Lactose Intolerance
3.7.1.2.8. Vitamin Production
3.7.1.2.9. Weight Management

3.7.1.3. Side Effects of Probiotics

3.7.2. Prebiotics
3.7.2.1. Sources of Prebiotics
3.7.2.2. Types of Prebiotics
3.7.2.2.1. Fructo-Oligosaccharides (FOS)
3.7.2.2.2. Galacto-Oligosaccharides (GOS)
3.7.2.2.3. Inulin

3.7.2.3. Key Therapeutic Areas
3.7.2.3.1. Antibiotic Associated Diarrhea (AAD)
3.7.2.3.2. Constipation
3.7.2.3.3. Gastrointestinal Disorders
3.7.2.3.4. Dysbiosis
3.7.2.4. Side Effects of Prebiotics

3.8. The Human Microbiome Project (HMP)
3.8.1. Project Approach
3.8.2. Project Initiatives
3.8.3. Project Achievements

3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)
3.10. Key Challenges in the Development of Microbiome Therapeutics
3.11. Future Perspectives

4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Microbiome Therapeutics: Clinical Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Target Indication
4.2.5. Analysis by Therapeutic Area
4.2.6. Analysis by Dosing Frequency
4.2.7. Analysis by Route of Administration
4.2.8. Analysis by Drug Formulation

4.3. Microbiome Therapeutics: Early-Stage Pipeline
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Molecule
4.3.3. Analysis by Type of Therapy
4.3.4. Analysis by Target Indication
4.3.5. Analysis by Therapeutic Area

4.4. Microbiome Therapeutics: List of Drug Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Location of Headquarters
4.4.3. Analysis by Company Size
4.4.4. Analysis by Company Size and Location of Headquarters
4.4.5. Leading Drug Developers: Analysis by Number of Microbiome Therapeutics

4.5. Grid Analysis: Microbiome and Key Therapeutic Areas

4.6. Microbiome Therapeutics: List of Discontinued Drugs
4.7. Emerging Role of Microbiome in Gut-Brain Axis
4.8. Microbiome Therapeutics: List of Technology Platforms

5. COMPANY AND DRUG PROFILES
5.1. Chapter Overview
5.2. 4D Pharma
5.2.1. Company Overview
5.2.2. Microbiome-based Product Portfolio
5.2.2.1. Blautix®
5.2.2.1.1. Drug Overview
5.2.2.1.2. Current Status of Development
5.2.2.1.3. Clinical Studies
5.2.2.1.4. Clinical Trial End-Point Analysis
5.2.3. Recent Developments and Future Outlook

5.3. Armata Pharmaceuticals
5.3.1. Company Overview
5.3.2. Microbiome-Based Product Portfolio
5.3.2.1. C16G2
5.3.2.1.1. Drug Overview
5.3.2.1.2. Current Status of Development
5.3.2.1.3. Clinical Studies
5.3.2.1.4. Clinical Trial End-Point Analysis
5.3.3. Recent Developments and Future Outlook

5.4. Evelo Biosciences
5.4.1. Company Overview
5.4.2. Microbiome-Based Product Portfolio
5.4.2.1. EDP1503
5.4.2.1.1. Drug Overview
5.4.2.1.2. Current Status of Development
5.4.2.1.3. Clinical Studies
5.4.2.1.4. Clinical Trial End-Point Analysis
5.4.3. Recent Developments and Future Outlook

5.5. Rebiotix (Acquired by Ferring Pharmaceuticals)
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Microbiome-Based Product Portfolio
5.5.3.1. RBX2660
5.5.3.1.1. Drug Overview
5.5.3.1.2. Current Status of Development
5.5.3.1.3. Clinical Studies
5.5.3.1.4. Clinical Trial End-Point Analysis
5.5.4. Recent Developments and Future Outlook

5.6. Seres Therapeutics
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Microbiome-Based Product Portfolio
5.6.3.1. SER-109
5.6.3.1.1. Drug Overview
5.6.3.1.2. Current Status of Development
5.6.3.1.3. Clinical Studies
5.6.3.1.4. Clinical Trial End-Point Analysis

5.6.3.2. SER-287
5.6.3.2.1. Current Status of Development
5.6.3.2.3. Clinical Studies
5.6.3.2.4. Clinical Trial End-Point Analysis
5.6.4. Recent Developments and Future Outlook

5.7. Vedanta Biosciences
5.7.1. Company Overview
5.7.2. Microbiome-Based Product Portfolio
5.7.2.1. VE303
5.7.2.1.1. Drug Overview
5.7.2.1.2. Current Status of Development
5.7.2.1.3. Clinical Studies
5.7.3.1.4. Clinical Trial End-Point Analysis
5.7.3. Recent Developments and Future Outlook

6. MICROBIOME DIAGNOSTICS: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Overview of Microbiome Diagnostic Tests
6.3. Microbiome Diagnostic Tests: Marketed and Under Development Products
6.3.1. Analysis by Stage of Development
6.3.2. Analysis by Type of Sample Required
6.3.3. Analysis by Target Indication 
6.3.4. Analysis by Therapeutic Area
6.3.5. Analysis by Purpose

6.4. Microbiome Diagnostic Tests: List of Diagnostic Developers
6.4.1. Analysis by Year of Establishment
6.4.2. Analysis by Location of Headquarters
6.4.3. Analysis by Company Size
6.4.4. Analysis by Company Size and Location of Headquarters
6.4.5. Leading Diagnostic Developers: Analysis by Number of Microbiome Diagnostics

6.5. Profiles of Prominent Diagnostic Developers
6.5.1. Enterome Bioscience
6.5.1.1. Company Overview
6.5.1.2. Service Portfolio

6.5.2. Vaiomer
6.5.2.1. Company Overview
6.5.2.2. Service Portfolio
6.6. Overview of Microbiome Screening / Profiling Tests
6.6.1. List of Microbiome Screening / Profiling Tests
6.6.2. List of Microbiome Screening / Profiling Test Developers

7. FECAL MICROBIOTA THERAPY (FMT)
7.1. Chapter Overview
7.2. Introduction to FMT
7.3. Historical Overview
7.4. FMT: Procedure and Clinical Relevance
7.4.1. Donor Selection
7.4.2. Administration Procedure
7.4.3. Routes of Administration
7.4.4. Consequences and Adverse Events
7.4.5. Clinical Guidelines Associated with FMT

7.5. Regulatory Guidelines Related to FMT
7.6. Insurance Coverage for FMT

7.7. FMT: Competitive Landscape
7.7.1. Marketed / Development Pipeline (Industry Players)
7.7.1.1. Analysis by Phase of Development
7.7.1.2. Analysis by Therapeutic Area
7.7.1.3. Analysis by Route of Administration

7.7.2. List of Developers (Industry Players)
7.7.2.1. Analysis by Year of Establishment
7.7.2.2. Analysis by Location of Headquarters
7.7.2.3. Analysis by Company Size

7.8. Clinical Trial Analysis (Non-Industry Sponsored)
7.8.1. Scope and Methodology
7.8.2. List of Clinical Trials
7.8.2.1. Analysis by Trial Registration Year
7.8.2.2. Analysis by Trial Status
7.8.2.3. Analysis by Phase of Development
7.8.2.4. Analysis by Patients Enrolled
7.8.2.5. Analysis of Number of Patients Enrolled by Trial Registration Year
7.8.2.6. Analysis by Therapeutic Area
7.8.2.7. Analysis by Popular Target Indications
7.8.2.8. Analysis by Trial Registration Year and Recruitment Status
7.8.2.9. Analysis by Study Design
7.8.2.10. Leading Non-Industry Players: Analysis by Number of Trials
7.8.2.11. Geographical Analysis by Number of Clinical Trials
7.8.2.12. Geographical Analysis by Enrolled Patient Population
7.8.2.13. Analysis by Type of Sponsor / Collaborator
7.8.2.14. Analysis by Trial Focus
7.8.2.15. Key Clinical Trials

7.9. Stool Banks
7.9.1. Introduction to Stool Banks
7.9.2. List of Stool Banks

7.9.3. Profiles of Prominent Stool Banks
7.9.3.1. AdvancingBio
7.9.3.1.1. Overview
7.9.3.1.2. Fecal Microbiota Preparation

7.9.3.2. Asia Microbiota bank
7.9.3.2.1. Overview
7.9.3.2.2. Fecal Microbiota Preparation

7.9.3.3. Enterobiotix
7.9.3.3.1. Overview
7.9.3.3.2. Fecal Microbiota Preparation

7.9.3.4. Flora Medicine
7.9.3.4.1. Overview
7.9.3.4.2. Fecal Microbiota Preparation

7.9.3.5. OpenBiome
7.9.3.5.1. Overview
7.9.3.5.2. Fecal Microbiota Preparation

8. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX
8.1. Chapter Overview
8.2. AC Matrix: An Overview
8.2.1. Strong Opportunity Areas
8.2.2. Average Opportunity Areas
8.2.3. Weak Opportunity Areas

8.3. AC Matrix: Analytical Methodology
8.4. AC Matrix: Plotting the Information
8.5. AC Matrix: Analyzing the Data
8.5.1. Strong Opportunity Areas
8.5.2. Average Opportunity Areas
8.5.3. Weak Opportunity Areas

9. MICROBIOME RELATED INITIATIVES OF BIG PHARMACEUTICAL PLAYERS
9.1. Chapter Overview
9.2. Scope and Methodology

9.3. Initiatives of Big Pharmaceutical Players
9.3.1. Analysis by Portfolio Diversity
9.3.2. Analysis by Phase of Development 
9.3.3. Analysis by Type of Molecule
9.3.4. Analysis by Type of Therapy
9.3.5. Analysis by Diversity of Therapeutic Areas

9.4. Benchmark Analysis of Big Pharmaceutical Players
9.4.1. Spider Web Analysis: Company A
9.4.2. Spider Web Analysis: Company B
9.4.3. Spider Web Analysis: Company C
9.4.4. Spider Web Analysis: Company D
9.4.5. Spider Web Analysis: Company E
9.4.6. Spider Web Analysis: Company F
9.4.7. Spider Web Analysis: Company G
9.4.8. Spider Web Analysis: Company H
9.4.9. Spider Web Analysis: Company I
9.4.10. Spider Web Analysis: Company J
9.4.11. Spider Web Analysis: Company K

10. START-UP HEALTH INDEXING
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Benchmark Analysis of Start-ups
10.3.1. Benchmark Analysis by Portfolio Diversity
10.3.2. Benchmark Analysis by Phase of Development 
10.3.3. Benchmark Analysis by Diversity in Therapeutic Areas
10.3.4. Benchmark Analysis by Funding Amount
10.3.5. Benchmark Analysis by Number of Investors
10.3.6. Benchmark Analysis by Progression in Funding
10.3.7. Benchmark Analysis by Partnership Activity
10.3.8. Benchmark Analysis by Patent Portfolio
10.3.9. Start-up Health Indexing: Roots Analysis Perspective
10.3.9.1. Short Profiles of Top Five Players
10.3.9.1.1. Evelo Biosciences
10.3.9.1.2. AOBiome Therapuetics
10.3.9.1.3. SFA Therapeutics
10.3.9.1.4. Azitra
10.3.9.1.5. Axial Biotherapeutics

11. KEY THERAPEUTIC AREAS
11.1. Chapter Overview
11.2. Metabolic Disorders
11.2.1. Diabetes
11.2.1.1. Disease Description
11.2.1.2. Associated Health Risks / Complications
11.2.1.3. Epidemiology
11.2.1.4. Disease Diagnosis
11.2.1.5. Current Treatment Options
11.2.1.5.1. Insulin Therapies
11.2.1.5.2. Non-Insulin Therapies
11.2.1.6. Side Effects of Current Treatment Options
11.2.1.7. Microbiome Therapeutics for Diabetes

11.2.2. Lactose Intolerance
11.2.2.1. Disease Description
1.2.2.2. Epidemiology
11.2.2.3. Current Treatment Options
11.2.2.4. Microbiome Therapeutics for Lactose Intolerance

11.2.3. Nonalcoholic Steatohepatitis (NASH)
11.2.3.1. Disease Description
11.2.3.2. Epidemiology
11.2.3.3. Current Treatment Options
11.2.3.4. Microbiome Therapeutics for NASH

11.2.4. Primary Hyperoxaluria
11.2.4.1. Disease Description
11.2.4.2. Epidemiology
11.2.4.3. Current Treatment Options
11.2.4.4. Microbiome Therapeutics for Primary Hyperoxaluria

11.2.5. Obesity
11.2.5.1. Disease Description
11.2.5.2. Epidemiology
11.2.5.3. Current Treatment Options
11.2.5.4. Side Effects of Current Treatment Options
11.2.5.5. Microbiome Therapeutics for Obesity

11.3. Digestive and Gastrointestinal Disorders
11.3.1. Crohn’s Disease
11.3.1.1. Disease Description
11.3.1.2. Epidemiology
11.3.1.3. Current Treatment Options
11.3.1.4. Side Effects of Current Treatment Options
11.3.1.5. Microbiome Therapeutics for Crohn’s Disease

11.3.2. Irritable Bowel Syndrome (IBS)
11.3.2.1. Disease Description
11.3.2.2. Epidemiology
11.3.2.3. Current Treatment Options
11.3.2.4. Microbiome Therapeutics for IBS

11.3.3. Ulcerative Colitis
11.3.3.1. Disease Description
11.3.3.2. Epidemiology
11.3.3.3. Current Treatment Options
11.3.3.4. Side Effects of Current Treatment Options
11.3.3.5. Microbiome Therapeutics for Ulcerative Colitis

11.4. Oncological Indications
11.4.1. Colorectal Cancer
11.4.1.1. Disease Description
11.4.1.2. Epidemiology
11.4.1.3. Current Treatment Options
11.4.1.4. Side Effects of Current Treatments
11.4.1.5. Microbiome Therapeutics for Colorectal Cancer

11.4.2. Lung Cancer
11.4.2.1. Disease Description
11.4.2.2. Epidemiology
11.4.2.3. Current Treatment Options
11.4.2.4. Side Effects of Current Treatment Options
11.4.2.5. Microbiome Therapeutics for Lung Cancer

11.5. Dermatological Disorders
11.5.1. Acne Vulgaris
11.5.1.1. Disease Description
11.5.1.2. Epidemiology
11.5.1.3. Current Treatment Options
11.5.1.4. Side Effects of Current Treatment Options
11.5.1.5. Microbiome Therapeutics for Acne Vulgaris

11.6. Infectious Diseases
11.6.1. Clostridium Difficile Infections (CDIs)
11.6.1.1. Disease Description
11.6.1.2. Epidemiology
11.6.1.3. Disease Diagnosis
11.6.1.4. Current Treatment Options
11.6.1.5. Side Effects of Current Treatment Options
11.6.1.6. Microbiome Therapeutics for CDI

11.6.2. Bacterial Vaginosis
11.6.2.1. Disease Description
11.6.2.2. Epidemiology
11.6.2.3. Current Treatment Options
11.6.2.4. Side Effects of Current Treatment Options
11.6.2.5. Microbiome Therapeutics for Bacterial Vaginosis

12. FUNDING AND INVESTMENT ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding

12.3. Microbiome Therapeutics and Diagnostics: List of Funding and Investments
12.3.1. Analysis by Number of Instances
12.3.2. Analysis by Amount Invested
12.3.3. Analysis by Type of Funding
12.3.4. Analysis by Type of Company
12.3.5. Analysis by Purpose of Funding
12.3.6. Analysis by Type of Molecule
12.3.7. Analysis by Target Indication 
12.3.8. Analysis by Therapeutic Area
12.3.9. Analysis by Geography
12.3.10. Most Active Players
12.3.11. Most Active Investors
12.3.12. Analysis by Type of Investors
12.3.13. Analysis by Location of Investors
12.4. Concluding Remarks

13. CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS
13.1. Chapter Overview
13.2. Manufacturing Microbiome Therapeutics
13.2.1. Key Steps Involved
13.2.2. Associated Challenges
13.2.3. Growing Demand for Contract Manufacturing Services

13.2.4. Contract Manufacturing Organizations (CMOs)
13.2.4.1. Introduction to Contract Manufacturing
13.2.4.2. List of Organizations Offering Services for Microbiome Therapeutics

13.2.5. In-House Manufacturers
13.2.5.1. Introduction to In-House Manufacturing
13.2.5.2. List of In-House Manufacturers

13.3. Microbiome Therapeutics-related R&D
13.3.1. Growing Demand for Contract Research Services
13.3.2. Contract Research Organizations (CROs)
13.3.2.1. Introduction to Contract Research
13.3.2.2. List of Organizations Offering Services for Microbiome Therapeutics

13.4. Key Considerations for Selecting a Suitable CMO / CRO Partner

14. BIG DATA AND MICROBIOME THERAPEUTICS
14.1. Chapter Overview
14.2. Introduction to Big Data
14.3. Internet of Things
14.4. Growing Interest in Big Data: Google Trends Analysis
14.5. Key Application Areas

14.6. Big Data in Microbiome Research
14.6.1. Microbiome Data and Personalized Medicine
14.6.2. Microbiome-related Data Management Challenges
14.6.3. National Microbiome Data Center

14.7. Big Data Services for Microbiome Research: List of Companies
14.8. Big Data Services for Microbiome Research: Profiles of Key Players
14.8.1. Human Longevity
14.8.1.1. Company Overview
14.8.1.2. Technology and Service Portfolio
14.8.1.3. Recent Developments

14.8.2. Resilient Biotics
14.8.2.1. Company Overview
14.8.2.2. Technology and Service Portfolio
14.8.2.3. Recent Developments

14.8.3. Resphera Biosciences
14.8.3.1. Company Overview
14.8.3.2. Technology and Service Portfolio

15. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Forecast Methodology

15.4. Overall Microbiome Therapeutics Market, 2019-2030
15.4.1. Microbiome Therapeutics Market: Distribution by Type of Therapy, 2025 and 2030
15.4.1.1. Microbiome Therapeutics Market for Prescription Drugs, 2019-2030
15.4.1.2. Microbiome Therapeutics Market for Prebiotic Drugs, 2019-2030
15.4.1.3. Microbiome Therapeutics Market for Probiotic Drugs, 2019-2030

15.4.2. Microbiome Therapeutics Market: Distribution by Type of Molecule, 2025 and 2030
15.4.2.1. Microbiome Therapeutics Market for Small Molecules, 2019-2030
15.4.2.2. Microbiome Therapeutics Market for Biologics, 2019-2030

15.4.3. Microbiome Therapeutics Market: Distribution by Target Indication, 2025 and 2030
15.4.3.1. Microbiome Therapeutics Market for Acne Vulgaris, 2019-2030
15.4.3.2. Microbiome Therapeutics Market for Atopic Dermatitis, 2019-2030
15.4.3.3. Microbiome Therapeutics Market for CDI, 2019-2030
15.4.3.4. Microbiome Therapeutics Market for Crohn’s Disease, 2019-2030
15.4.3.5. Microbiome Therapeutics Market for Dental Caries, 2019-2030
15.4.3.6. Microbiome Therapeutics Market for Diabetes, 2019-2030
15.4.3.7. Microbiome Therapeutics Market for IBS, 2019-2030
15.4.3.8. Microbiome Therapeutics Market for Lactose Intolerance, 2019-2030
15.4.3.9. Microbiome Therapeutics Market for Lung Cancer, 2019-2030
15.4.3.10. Microbiome Therapeutics Market for NASH, 2019-2030
15.4.3.11. Microbiome Therapeutics Market for Primary Hyperoxaluria, 2019-2030
15.4.3.12. Microbiome Therapeutics Market for Psoriasis, 2019-2030
15.4.3.13. Microbiome Therapeutics Market for Ulcerative Colitis, 2019-2030

15.4.4. Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2025 and 2030
15.4.4.1. Microbiome Therapeutics Market for Autoimmune Disorders, 2019-2030
15.4.4.2. Microbiome Therapeutics Market for Dental Disorders, 2019-2030
15.4.4.3. Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, 2019-2030
15.4.4.4. Microbiome Therapeutics Market for Dermatological Disorders, 2019-2030
15.4.4.5. Microbiome Therapeutics Market for Infectious Diseases, 2019-2030
15.4.4.6. Microbiome Therapeutics Market for Metabolic Disorders, 2019-2030
15.4.4.7. Microbiome Therapeutics Market for Oncology, 2019-2030

15.4.5. Microbiome Therapeutics Market: Distribution by Key Geographical Regions, 2025 and 2030
15.4.5.1. Microbiome Therapeutics Market in North America, 2019-2030
15.4.5.2. Microbiome Therapeutics Market in Europe, 2019-2030
15.4.5.3. Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, 2019-2030
15.4.6. Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2025 and 2030
15.5. Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2019-2030
15.5.1. Drug-wise Sales Forecast
15.5.1.1. IBP-9414 (Infant Bacterial Therapeutics)
15.5.1.2. Sales Forecast (USD Million)
15.5.1.3. Net Present Value (USD Million)
15.5.1.4. Value Creation Analysis

15.5.2.1. Oxabact (OxThera)
15.5.2.2. Sales Forecast (USD Million)
15.5.2.3. Net Present Value (USD Million)
15.5.2.4. Value Creation Analysis

15.5.3.1. RBX2660 (Rebiotix)
15.5.3.2. Sales Forecast (USD Million)
15.5.3.3. Net Present Value (USD Million)
15.5.3.4. Value Creation Analysis

15.5.4.1. RP-G28 (Ritter Pharmaceuticals)
15.5.4.2. Sales Forecast (USD Million)
15.5.4.3. Net Present Value (USD Million)
15.5.4.4. Value Creation Analysis

15.5.5.1. SER-109 (Seres Therapeutics)
15.5.5.2. Sales Forecast (USD Million)
15.5.5.3. Net Present Value (USD Million)
15.5.5.4. Value Creation Analysis

16. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
16.1. Chapter Overview
16.2. Scope and Limitations
16.3 Forecast Methodology
16.4. Overall Microbiome Diagnostics Market, 2019-2030
16.4.1. Overall Microbiome Diagnostics Market, 2019-2030 (By Value)
16.4.2. Overall Microbiome Diagnostics Market, 2019-2030 (By Volume)

16.5. Microbiome Diagnostics Market: Distribution by Target Indications, 2019, 2030
16.5.1. Microbiome Diagnostics Market: Distribution by Target Indications, 2019 and 2030 (By Value)
16.5.1.1. Microbiome Diagnostics Market for Colorectal Cancer, 2019-2030 (By Value)
16.5.1.2. Microbiome Diagnostics Market for Diabetes, 2019-2030 (By Value)
16.5.1.3. Microbiome Diagnostics Market for IBD, 2019-2030 (By Value)
16.5.1.4. Microbiome Diagnostics Market for IBS, 2019-2030 (By Value)
16.5.1.5. Microbiome Diagnostics Market for NASH, 2019-2030 (By Value)
16.5.1.6. Microbiome Diagnostics Market for Obesity, 2019-2030 (By Value)
16.5.1.7. Microbiome Diagnostics Market for Others, 2019-2030 (By Value)

16.5.2. Microbiome Diagnostics Market: Distribution by Target Indications, 2019 and 2030 (By Volume)
16.5.2.1. Microbiome Diagnostics Market for Colorectal Cancer, 2019-2030 (By Volume)
16.5.2.2. Microbiome Diagnostics Market for Diabetes, 2019-2030 (By Volume)
16.5.2.3. Microbiome Diagnostics Market for IBD, 2019-2030 (By Volume)
16.5.2.4. Microbiome Diagnostics Market for IBS, 2019-2030 (By Volume)
16.5.2.5. Microbiome Diagnostics Market for NASH, 2019-2030 (By Volume)
16.5.2.6. Microbiome Diagnostics Market for Obesity, 2019-2030 (By Volume)
16.5.2.7. Microbiome Diagnostics Market for Others, 2019-2030 (By Volume)

16.6. Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019-2030
16.6.1. Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019 and 2030 (By Value)
16.6.1.2. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2019-2030 (By Value)
16.6.1.2. Microbiome Diagnostics Market for Metabolic Disorders, 2019-2030 (By Value)
16.6.1.3. Microbiome Diagnostics Market for Oncology, 2019-2030 (By Value)
16.6.1.4. Microbiome Diagnostics Market for Others, 2019-2030 (By Value)

16.6.2. Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019 and 2030 (By Volume)
16.6.2.1. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2019-2030 (By Volume)
16.6.2.2. Microbiome Diagnostics Market for Metabolic Disorders, 2019-2030 (By Volume)
16.6.2.3. Microbiome Diagnostics Market for Oncology, 2019-2030 (By Volume)
16.6.2.4. Microbiome Diagnostics Market for Others, 2019-2030 (By Volume)

16.7. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019-2030
16.7.1. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019 and 2030 (By Value)
16.7.1.1. Microbiome Diagnostics Market in North America, 2019-2030 (By Value)
16.7.1.2. Microbiome Diagnostics Market in Europe, 2019-2030 (By Value)
16.7.1.3. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2019-2030 (By Value)

16.7.2. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019 and 2030 (By Volume)
16.7.2.1. Microbiome Diagnostics Market in North America, 2019-2030 (By Volume)
16.7.2.2. Microbiome Diagnostics Market in Europe, 2019-2030 (By Volume)
16.7.2.3. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2019-2030 (By Volume)

17. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Scope and Limitations
17.3. Forecast Methodology
17.4. Overall FMT Market, 2019-2030
17.4.1. Overall FMT Market, 2019-2030 (By Value)
17.4.2. Overall FMT Market, 2019-2030 (By Volume)

17.5. Overall Microbiome Market by Product Offerings, 2019-2030

18. CASE STUDY: MICROBIOME-BASED PRODUCTS IN OTHER INDUSTRIES
18.1. Chapter Overview
18.2. List of Microbiome Products in Other Industries
18.2.1. Applications of Microbiome Based Products in Cosmetics and Food Industry
18.3. Applications of Microbiome Based Products in Agriculture Industry
18.4. Future Prospects

19. CONCLUDING REMARKS

20. EXECUTIVE INSIGHTS
20.1 Chapter Overview
20.2. Floragraph
20.2.1. Company / Organization Snapshot
20.2.2. Interview Transcript: Alicia Scheffer, Chief Executive Officer

20.3. Rebiotix
20.3.1. Company / Organization Snapshot
20.3.2. Interview Transcript: Lee Jones, President and Chief Executive Officer

20.4. S-Biomedic
20.4.1. Company / Organization Snapshot
20.4.2. Interview Transcript: Veronika Oudova, Co-founder and Chief Executive Officer

20.5. Whole Biome
20.5.1. Company / Organization Snapshot
20.5.2. Interview Transcript: Colleen Cutcliffe, Co-founder and Chief Executive Officer

20.6. Siolta Therapeutics
20.6.1. Company / Organization Snapshot
20.6.2. Interview Transcript: Nikole E Kimes, Co-founder and Vice President

20.7. OpenBiome
20.7.1. Company / Organization Snapshot
20.7.2. Interview Transcript: James Burges, Executive Director

20.8. Assembly Biosciences
20.8.1. Company / Organization Snapshot
20.8.2. Interview Transcript: JP Benya, Vice President, Business Development

20.9. List Biological Laboratories
20.9.1. Company / Organization Snapshot
20.9.2. Interview Transcript: Debbie Pinkston, Vice President, Sales and Business Development

20.10. Metabiomics
20.10.1. Company / Organization Snapshot
20.10.2. Interview Transcript: Gregory J Kuehn, Vice President, Business Development and Marketing

20.11. MicroBiome Therapeutics
20.11.1. Company / Organization Snapshot
20.11.2. Interview Transcript: Mark Heiman, Chief Scientific Officer and Vice President, Research

20.12. Universal Stabilization Technologies
20.12.1. Company / Organization Snapshot
20.12.2. Interview Transcript: Alexander Segal, Vice President, Business Development

20.13. BiomX
20.13.1. Company / Organization Snapshot
20.13.2. Interview Transcript: Assaf Oron, Chief Business Officer

20.14. Da Volterra
20.14.1. Company / Organization Snapshot
20.14.2. Interview Transcript: Pierre-Alain Bandinelli, Chief Business Officer

20.15. Chung Mei Pharmaceutical
20.15.1. Company / Organization Snapshot
20.15.2. Interview Transcript: Alexander Lin, Associate General Manager

20.16. Pacific Northwest National Laboratories
20.16.1. Company / Organization Snapshot
20.16.2. Interview Transcript: Aaron Wright, Senior Scientist

21. APPENDIX I: TABULATED DATA

22. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Benefits of the Human Microbiota
Figure 3.2 Factors Affecting Gut Flora
Figure 3.3 Factors Affecting Gut Microbiota in Infants
Figure 3.4 Impact of Diet on Gut Microbiota
Figure 3.5 Types of Microbiome Therapeutics
Figure 3.6 Approaches to Design Microbiome Therapeutics
Figure 3.7 Health Benefits of Probiotics
Figure 3.8 Mechanisms of Action of Probiotics
Figure 3.9 Beneficial Bacterial Strains for Probiotics
Figure 3.10 Key Achievements of the Human Microbiome Project (HMP)
Figure 3.11 Key Challenges in Developing Microbiome Therapeutics
Figure 4.1 Microbiome Therapeutics Clinical Pipeline: Distribution by Phase of Development
Figure 4.2 Microbiome Therapeutics Clinical Pipeline: Distribution by Type of Molecule
Figure 4.3 Microbiome Therapeutics Clinical Pipeline: Distribution by Type of Therapy
Figure 4.4 Microbiome Therapeutics Clinical Pipeline: Distribution by Target Indication
Figure 4.5 Microbiome Therapeutics Clinical Pipeline: Distribution by Therapeutic Area
Figure 4.6 Microbiome Therapeutics Clinical Pipeline: Distribution by Dosing Frequency
Figure 4.7 Microbiome Therapeutics Clinical Pipeline: Distribution by Route of Administration
Figure 4.8 Microbiome Therapeutics Clinical Pipeline: Distribution by Drug Formulation
Figure 4.9 Microbiome Therapeutics Preclinical Pipeline: Distribution by Phase of Development
Figure 4.10 Microbiome Therapeutics Preclinical Pipeline: Distribution by Type of Molecule
Figure 4.11 Microbiome Therapeutics Preclinical Pipeline: Distribution by Type of Therapy
Figure 4.12 Microbiome Therapeutics Preclinical Pipeline: Distribution by Target Indication
Figure 4.13 Microbiome Therapeutics Preclinical Pipeline: Distribution by Therapeutic Area
Figure 4.14 Microbiome Therapeutic Developers: Distribution by Year of Establishment
Figure 4.15 Microbiome Therapeutic Developers: Distribution by Location of Headquarters
Figure 4.16 Microbiome Therapeutic Developers: Distribution by Company Size
Figure 4.17 Microbiome Therapeutic Developers: Distribution by Company Size and Location of Headquarters
Figure 4.18 Microbiome Therapeutic Developers: Most Active Players
Figure 4.19 Grid Analysis: Microbiome and Key Therapeutic Areas
Figure 5.1 4D Pharma: Microbiome-Based Product Portfolio
Figure 5.2 Blautix®: Clinical Trial Timeline and Patient Segment
Figure 5.3 Armata Pharmaceuticals: Microbiome-Based Product Portfolio
Figure 5.4 C16G2: Clinical Trial Timeline and Patient Segment
Figure 5.5 Evelo Biosciences: Microbiome-Based Product Portfolio
Figure 5.6 EDP1503: Clinical Trial Timeline and Patient Segment
Figure 5.7 Ferring Pharmaceuticals: Annual Revenues, 2014-2018 (DKK Million)
Figure 5.8 Rebiotix: Microbiome-Based Product Portfolio
Figure 5.9 RBX2660: Clinical Trial Timeline and Patient Segment
Figure 5.10 Seres Therapeutics: Annual Revenues, 2016-H1 2019 (USD Million)
Figure 5.11 Seres Therapeutics: Microbiome-Based Product Portfolio
Figure 5.12 SER-109: Clinical Trial Timeline and Patient Segment
Figure 5.13 SER-287: Clinical Trial Timeline and Patient Segment
Figure 5.14 Vedanta Biosciences: Microbiome-Based Product Portfolio
Figure 5.15 VER-303: Clinical Trial Timeline and Patient Segment
Figure 6.1 Key Steps in 16S rRNA Gene Sequence Analysis
Figure 6.2 Microbiome Diagnostics: Distribution by Stage of Development
Figure 6.3 Microbiome Diagnostics: Distribution by Type of Sample Required
Figure 6.4 Microbiome Diagnostics: Distribution by Target Indication
Figure 6.5 Microbiome Diagnostics: Distribution by Therapeutic Area
Figure 6.6 Microbiome Diagnostics: Distribution by Purpose
Figure 6.7 Microbiome Diagnostic Developers: Distribution by Year of Establishment
Figure 6.8 Microbiome Diagnostic Developers: Distribution by Location of Headquarters
Figure 6.9 Microbiome Diagnostic Developers: Distribution by Company Size
Figure 6.10 Microbiome Diagnostic Developers: Distribution by Company Size and Location of Headquarters
Figure 6.11 Microbiome Diagnostic Developers: Most Active Players
Figure 7.1 Working Mechanism of a Microflora Refinement System
Figure 7.2 FMT: Distribution by Phase of Development
Figure 7.3 FMT: Distribution by Therapeutic Area
Figure 7.4 FMT: Distribution by Route of Administration
Figure 7.5 FMT Developers: Distribution by Year of Establishment
Figure 7.6 FMT Developers: Distribution by Location of Headquarters
Figure 7.7 FMT Developers: Distribution by Company Size
Figure 7.8 Clinical Trial Analysis: Cumulative Distribution of Number of Trials by Registration Year, 2011-2019
Figure 7.9 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.10 Clinical Trial Analysis: Distribution by Phase of Development
Figure 7.11 Clinical Trial Analysis: Distribution by Patients Enrolled
Figure 7.12 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2011-2019
Figure 7.13 Clinical Trial Analysis: Distribution by Popular Target Indications
Figure 7.14 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 7.15 Clinical Trial Analysis: Distribution by Recruitment Status and Trial Registration Year
Figure 7.16 Clinical Trial Analysis: Distribution by Study Design
Figure 7.17 Clinical Trial Analysis: Leading Non-Industry Players by Number of Trials
Figure 7.18 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Figure 7.19 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.20 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.21 Clinical Trial Analysis: Focus Areas
Figure 7.22 Steps Involved in the Process of Stool Donation
Figure 8.1 AC Matrix: Pictorial Representation
Figure 8.2 AC Matrix: Positioning of Different Indications
Figure 9.1 Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
Figure 9.2 Big Pharma Players: Analysis by Portfolio Diversity
Figure 9.3 Big Pharma Players: Analysis by Phase of Development
Figure 9.4 Big Pharma Players: Analysis by Type of Molecule
Figure 9.5 Big Pharma Players: Analysis by Type of Therapy
Figure 9.6 Big Pharma Players: Analysis by Diversity of Therapeutic Areas
Figure 9.7 Spider Web Analysis: Company A
Figure 9.8 Spider Web Analysis: Company B
Figure 9.9 Spider Web Analysis: Company C
Figure 9.10 Spider Web Analysis: Company D
Figure 9.11 Spider Web Analysis: Company E
Figure 9.12 Spider Web Analysis: Company F
Figure 9.13 Spider Web Analysis: Company G
Figure 9.14 Spider Web Analysis: Company H
Figure 9.15 Spider Web Analysis: Company I
Figure 9.16 Spider Web Analysis: Company J
Figure 9.17 Spider Web Analysis: Company K
Figure 10.1 Benchmark Analysis of Start-ups: Distribution by Portfolio Diversity
Figure 10.2 Benchmark Analysis of Start-ups: Distribution by Phase of Development
Figure 10.3 Benchmark Analysis of Start-ups: Distribution by Therapeutic Areas
Figure 10.4 Benchmark Analysis of Start-ups: Distribution by Funding Amount
Figure 10.5 Benchmark Analysis of Start-ups: Distribution by Number of Investors
Figure 10.6 Benchmark Analysis of Start-ups: Distribution by Progression in Funding
Figure 10.7 Benchmark Analysis of Start-ups: Distribution by Partnership Activity
Figure 10.8 Benchmark Analysis of Start-ups: Distribution by Patent Portfolio
Figure 10.9 Start-up Health Indexing: Roots Analysis Perspective
Figure 11.1 Diabetes: Diagnostic Limits for Plasma Glucose Levels
Figure 11.2 Non-Insulin Therapies for Diabetes
Figure 11.3 Weight Categories as per BMI Calculations
Figure 11.4 Causes of Obesity in Children
Figure 11.5 Obese Population: Distribution by Key Regions
Figure 12.1 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment
Figure 12.2 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2013-2019
Figure 12.3 Funding and Investment Analysis: Distribution by Type of Funding and Year of Investment, 2013-2019
Figure 12.4 Funding and Investment Analysis: Cumulative Amount Invested, 2013-2019 (USD Million)
Figure 12.5 Funding and Investment Analysis: Year-Wise Distribution by Amount Invested and Type of Funding, 2013-2019 (USD Million)
Figure 12.6 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2013-2019
Figure 12.7 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2013-2019 (USD Million)
Figure 12.8 Funding and Investment Analysis: Summary of Amount Invested, 2013-2019 (USD Million)
Figure 12.9 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Company, 2013-2019 (USD Million)
Figure 12.10 Funding and Investment Analysis: Distribution of the Total Amount Invested by Purpose of Funding, 2013-2019 (USD Million)
Figure 12.11 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Product, 2013-2019 (USD Million)
Figure 12.12 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Product and Funding Type, 2013-2019 (USD Million)
Figure 12.13 Funding and Investment Analysis: Distribution by Therapeutic Area
Figure 12.14 Funding and Investment Analysis: Distribution of the Total Amount Invested by Therapeutic Area, 2013-2019 (USD Million)
Figure 12.15 Funding and Investment Analysis: Distribution by Target Indication
Figure 12.16 Funding and Investment Analysis: Distribution of the Total Amount Invested by Target Indication, 2013-2019 (USD Million)
Figure 12.17 Funding and Investment Analysis: Distribution by Geography
Figure 12.18 Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 12.19 Funding and Investment Analysis: Most Active Players by Number of Instances and Amount Invested, 2013-2019 (USD Million)
Figure 12.20 Funding and Investment Analysis: Most Active Investors by Number of Instances
Figure 12.21 Funding and Investment Analysis: Distribution by Type of Investors
Figure 12.22 Funding and Investment Analysis: Distribution by Location of Investors
Figure 12.23 Funding and Investment Summary, 2013-2019 (USD Million)
Figure 13.1 Microbiome Therapeutics Manufacturing Process
Figure 13.2 Challenges Related to Manufacturing Microbiome Therapeutics
Figure 13.3 Strategies to Optimize Microbiome Therapeutic Manufacturing Operations
Figure 13.4 Survey Respondents (December 2018): Distribution by Respondent Particulars
Figure 13.5 Microbiome Therapeutics: Distribution by Manufacturing Preference
Figure 13.6 Survey Respondents (June 2019): Distribution by Respondent Particulars
Figure 13.7 Microbiome Therapeutics: Distribution by Most Popular Analytical Techniques
Figure 14.1 Big Data: The Three V’s
Figure 14.2 Internet of Things: Framework
Figure 14.3 Internet of Things: Applications in Healthcare
Figure 14.4 Big Data: Google Trends
Figure 14.5 Big Data and Microbiome: Google Trends
Figure 14.6 Big Data: Key Application Areas
Figure 14.7 Big Data: Opportunities in Healthcare
Figure 14.8 Big Data: Key Benefits for Pharmaceutical and Biotechnology Products
Figure 14.8 Challenges Associated with Microbiome-related Big Data Management
Figure 15.1 Overall Microbiome Therapeutics Market, 2019-2030 (USD Billion)
Figure 15.2 Microbiome Therapeutics Market: Distribution by Type of Therapy, 2025 and 2030
Figure 15.3 Microbiome Therapeutics Market for Prescription Drugs, 2019-2030 (USD Million)
Figure 15.4 Microbiome Therapeutics Market for Prebiotic Drugs, 2019-2030 (USD Million)
Figure 15.5 Microbiome Therapeutics Market for Probiotic Drugs, 2019-2030 (USD Million)
Figure 15.6 Microbiome Therapeutics Market: Distribution by Type of Molecule, 2025 and 2030
Figure 15.7 Microbiome Therapeutics Market for Small Molecules, 2019-2030 (USD Million)
Figure 15.8 Microbiome Therapeutics Market for Biologics, 2019-2030 (USD Million)
Figure 15.9 Microbiome Therapeutics Market: Distribution by Target Indication, 2025 and 2030
Figure 15.10 Microbiome Therapeutics Market for Acne Vulgaris, 2019-2030 (USD Million)
Figure 15.11 Microbiome Therapeutics Market for Atopic Dermatitis, 2019-2030 (USD Million)
Figure 15.12 Microbiome Therapeutics Market for CDI, 2019-2030 (USD Million)
Figure 15.13 Microbiome Therapeutics Market for Crohn’s Disease, 2019-2030 (USD Million)
Figure 15.14 Microbiome Therapeutics Market for Dental Caries, 2019-2030 (USD Million)
Figure 15.15 Microbiome Therapeutics Market for Diabetes, 2019-2030 (USD Million)
Figure 15.16 Microbiome Therapeutics Market for IBS, 2019-2030 (USD Million)
Figure 15.17 Microbiome Therapeutics Market for Lactose Intolerance, 2019-2030 (USD Million)
Figure 15.18 Microbiome Therapeutics Market for Lung Cancer, 2019-2030 (USD Million)
Figure 15.19 Microbiome Therapeutics Market for NASH, 2019-2030 (USD Million)
Figure 15.20 Microbiome Therapeutics Market for Primary Hyperoxaluria, 2019-2030 (USD Million)
Figure 15.21 Microbiome Therapeutics Market for Psoriasis, 2019-2030 (USD Million)
Figure 15.22 Microbiome Therapeutics Market for Ulcerative Colitis, 2019-2030 (USD Million)
Figure 15.23 Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2025 and 2030
Figure 15.24 Microbiome Therapeutics Market for Autoimmune Disorders, 2019-2030 (USD Million)
Figure 15.25 Microbiome Therapeutics Market for Dental Disorders, 2019-2030 (USD Million)
Figure 15.26 Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, 2019-2030 (USD Million)
Figure 15.27 Microbiome Therapeutics Market for Dermatological Disorders, 2019-2030 (USD Million)
Figure 15.28 Microbiome Therapeutics Market for Infectious Diseases, 2019-2030 (USD Million)
Figure 15.29 Microbiome Therapeutics Market for Metabolic Disorders, 2019-2030 (USD Million)
Figure 15.30 Microbiome Therapeutics Market for Oncology, 2019-2030 (USD Million)
Figure 15.31 Microbiome Therapeutics Market: Distribution by Key Geographical Regions, 2025 and 2030
Figure 15.32 Microbiome Therapeutics Market in North America, 2019-2030 (USD Million)
Figure 15.33 Microbiome Therapeutics Market in Europe, 2019-2030 (USD Million)
Figure 15.34 Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, 2019-2030 (USD Million)
Figure 15.35 Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2025 and 2030
Figure 15.36 Microbiome Therapeutics Market: Distribution by Leading Drugs, 2019-2030
Figure 15.37 IBP-9414 (Infant Bacterial Therapeutics): Target Patient Population
Figure 15.38 IBP-9414 (Infant Bacterial Therapeutics): Sales Forecast, till 2030 (USD Million)
Figure 15.39 Oxabact® (OxThera): Target Patient Population
Figure 15.40 Oxabact® (OxThera): Sales Forecast, till 2030 (USD Million)
Figure 15.41 RBX2660 (Rebiotix): Target Patient Population
Figure 15.42 RBX2660 (Rebiotix): Sales Forecast, till 2030 (USD Million)
Figure 15.43 RP-G28 (Ritter Pharmaceuticals): Target Patient Population
Figure 15.44 RP-G28 (Ritter Pharmaceuticals): Sales Forecast, till 2030 (USD Million)
Figure 15.45 SER-109 (Seres Therapeutics): Target Patient Population
Figure 15.46 SER-109 (Seres Therapeutics): Sales Forecast, till 2030 (USD Million)
Figure 16.1 Overall Microbiome Diagnostics Market, 2019-2030 (USD Million)
Figure 16.2 Overall Microbiome Diagnostics Market, 2019-2030 (Units, Volume)
Figure 16.3 Microbiome Diagnostics Market: Distribution by Target Indications, 2019 and 2030
Figure 16.4 Microbiome Diagnostics Market for Colorectal Cancer, 2019-2030 (USD Million)
Figure 16.5 Microbiome Diagnostics Market for Diabetes, 2019-2030 (USD Million)
Figure 16.6 Microbiome Diagnostics Market for IBD, 2019-2030 (USD Million)
Figure 16.7 Microbiome Diagnostics Market for IBS, 2019-2030 (USD Million)
Figure 16.8 Microbiome Diagnostics Market for NASH, 2019-2030 (USD Million)
Figure 16.9 Microbiome Diagnostics Market for Obesity, 2019-2030 (USD Million)
Figure 16.10 Microbiome Diagnostics Market for Others, 2019-2030 (USD Million)
Figure 16.11 Microbiome Diagnostics Market: Distribution by Target Indications, 2019-2030 (Units, Volume)
Figure 16.12 Microbiome Diagnostics Market for Colorectal Cancer, 2019-2030 (Units, Volume)
Figure 16.13 Microbiome Diagnostics Market for Diabetes, 2019-2030 (Units, Volume)
Figure 16.14 Microbiome Diagnostics Market for IBD, 2019-2030 (Units, Volume)
Figure 16.15 Microbiome Diagnostics Market for IBS, 2019-2030 (Units, Volume)
Figure 16.16 Microbiome Diagnostics Market for NASH, 2019-2030 (Units, Volume)
Figure 16.17 Microbiome Diagnostics Market for Obesity, 2019-2030 (Units, Volume)
Figure 16.18 Microbiome Diagnostics Market for Others, 2019-2030 (Units, Volume)
Figure 16.19 Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019 and 2030
Figure 16.20 Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2019-2030 (USD Million)
Figure 16.21 Microbiome Diagnostics Market for Metabolic Disorders, 2019-2030 (USD Million)
Figure 16.22 Microbiome Diagnostics Market for Oncology, 2019-2030 (USD Million)
Figure 16.23 Microbiome Diagnostics Market for Others, 2019-2030 (USD Million)
Figure 16.24 Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019-2030 (Units, Volume)
Figure 16.25 Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2019-2030 (Units, Volume)
Figure 16.26 Microbiome Diagnostics Market for Metabolic Disorders, 2019-2030 (Units, Volume)
Figure 16.27 Microbiome Diagnostics Market for Oncology, 2019-2030 (Units, Volume)
Figure 16.28 Microbiome Diagnostics Market for Others, 2019-2030 (Units, Volume)
Figure 16.29 Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019 and 2030
Figure 16.30 Microbiome Diagnostics Market in North America, 2019-2030 (USD Million)
Figure 16.31 Microbiome Diagnostics Market in Europe, 2019-2030 (USD Million)
Figure 16.32 Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2019-2030 (USD Million)
Figure 16.33 Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019 and 2030 (Units, Volume)
Figure 16.34 Microbiome Diagnostics Market in North America, 2019-2030 (Units, Volume)
Figure 16.35 Microbiome Diagnostics Market in Europe, 2019-2030 (Units, Volume)
Figure 16.36 Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2019-2030 (Units, Volume)
Figure 17.1 Fecal Microbiota Therapies: Roots Analysis Forecasting Approach
Figure 17.2 Overall FMT Market, 2019-2030 (USD Million)
Figure 17.3 Overall FMT Market, 2019-2030 (Units, Volume)
Figure 17.4 Overall Microbiome Market by Product Offerings: Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Billion)

List Of Tables

Table 3.1 Types of Microbiota in the GI Tract
Table 3.2 Common Instances of Misuse of Antibiotics
Table 3.3 Impact of Antibiotics on Intestinal Microflora
Table 3.4 List of Microorganisms Classified as Class 1 Carcinogens by the IARC
Table 3.5 Relationship Between Microbiome and Disease
Table 3.6 Impact of Drug-Microbiome Interactions
Table 3.7 List of Foods Containing Prebiotics
Table 4.1 Microbiome Therapeutics: Clinical Pipeline
Table 4.2 Microbiome Therapeutics Clinical Pipeline: Information on Type of Molecule and Route of Administration
Table 4.3 Microbiome Therapeutics Clinical Pipeline: Additional Information
Table 4.4 Microbiome Therapeutics: Early-Stage Pipeline
Table 4.5 Microbiome Therapeutics Early-Stage Pipeline: Additional Information
Table 4.6 Microbiome Therapeutics: List of Drug Developers
Table 4.7 Microbiome Therapeutics: List of Discontinued Drugs
Table 4.8 Microbiome Therapeutics: List of Technology Platforms
Table 5.1 Blautix®: Current Status of Development
Table 5.2 4D Pharma: Recent Developments and Future Outlook
Table 5.3 C16G2: Current Status of Development
Table 5.4 Armata Pharmaceuticals: Recent Developments and Future Outlook
Table 5.5 EDP1503: Current Status of Development
Table 5.6 Evelo Biosciences: Recent Developments and Future Outlook
Table 5.7 RBX2660: Current Status of Development
Table 5.8 Rebiotix: Recent Developments and Future Outlook
Table 5.9 SER-109: Current Status of Development
Table 5.10 SER-287: Current Status of Development
Table 5.11 Seres Therapeutics: Recent Developments and Future Outlook
Table 5.12 VE303: Current Status of Development
Table 5.13 VE416: Current Status of Development
Table 5.14 Vedanta Biosciences: Recent Developments and Future Outlook
Table 6.1 Microbiome Diagnostics: Marketed and Development Pipeline
Table 6.2 Microbiome Diagnostics: List of Developers
Table 6.3 Microbiome Screening / Profiling Tests: Marketed and Development Pipeline
Table 6.4 Microbiome Screening / Profiling Tests: List of Developers
Table 7.1 Comparison between Various Routes of Administration of FMT
Table 7.2 FMT: Summary of Clinical Guidelines
Table 7.3 FMT: Summary of Insurance Coverage Payer
Table 7.4 FMT: Marketed and Development Pipeline
Table 7.5 FMT: List of Developers
Table 7.6 FMT: List of Clinical Trials (Non-Industry Sponsored)
Table 7.7 Clinical Trial Analysis: Most Important Trials to Watch
Table 7.8 List of Stool Banks for FMT Development
Table 7.9 FMT and Human Microbiome Transplant (HMT): Key Differences in Processing
Table 7.10 Flora Medicine: FMT Treatment Cost
Table 7.11 OpenBiome: Types of FMT Formulations
Table 11.1 Diabetes: Current Treatment Options
Table 11.2 Diabetes: Side Effects of Current Treatment Options
Table 11.3 Microbiome Therapeutics Pipeline for Diabetes
Table 11.4 Microbiome Therapeutics Pipeline for Lactose Intolerance
Table 11.5 Microbiome Therapeutics Pipeline for NASH
Table 11.6 Microbiome Therapeutics Pipeline for Primary Hyperoxaluria
Table 11.7 Obesity: Side Effects of Current Treatment Options
Table 11.8 Microbiome Therapeutic Pipeline for Obesity
Table 11.9 Crohn’s Disease: Current Treatment Options
Table 11.10 Crohn’s Disease: Side Effects of Current Treatment Options
Table 11.11 Microbiome Therapeutics Pipeline for Crohn’s Disease
Table 11.12 IBS: Current Treatment Options
Table 11.13 Microbiome Therapeutics Pipeline for IBS
Table 11.14 Ulcerative Colitis: Current Treatment Options
Table 11.15 Ulcerative Colitis: Side Effects of Current Treatment Options
Table 11.16 Microbiome Therapeutics Pipeline for Ulcerative Colitis
Table 11.17 Colorectal Cancer: Side Effects of Current Treatment Options
Table 11.18 Microbiome Therapeutics Pipeline for Colorectal Cancer
Table 11.19 Lung Cancer: Current Treatment Options
Table 11.20 Lung Cancer: Side Effects of Current Treatment Options
Table 11.21 Microbiome Therapeutics Pipeline for Lung Cancer
Table 11.22 Acne Vulgaris: Current Treatment Options
Table 11.23 Acne Vulgaris: Side Effects of Current Treatment Options
Table 11.24 Microbiome Therapeutics Pipeline for Acne Vulgaris
Table 11.25 CDI: Diagnostic Testing
Table 11.26 CDI: Severity Scoring System and Treatment Options
Table 11.27 CDI: Side Effects of Current Treatment Options
Table 11.28 Microbiome Therapeutics Pipeline for CDI
Table 11.29 Bacterial Vaginosis: Current Treatment Options
Table 11.30 Bacterial Vaginosis: Side Effects of Current Treatment Options
Table 11.31 Microbiome Therapeutics Pipeline for Bacterial Vaginosis
Table 12.1 Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Funding Type, Year, Amount and Investor, till 2019
Table 12.2 Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Type of Product, Target Indication and Focus Area, till 2019
Table 12.3 Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Type of Investor and Headquarter Location, till 2019
Table 13.1 List of Microbiome Contract Manufacturers: Information on Year of Establishment, Headquarters, Company Size and Type of Manufacturer
Table 13.2 List of Microbiome Contract Manufacturers: Information on Scale of Operation, Facility Location and Production Capacity
Table 13.3 List of In-House Microbiome Manufacturers: Information on Year of Establishment, Headquarters and Company Size
Table 13.4 List of CROs Offering Microbiome Research Services: Information on Year of Establishment, Headquarter and Company Size
Table 13.5 List of CROs Offering Microbiome Research Services: Information on Type of Services
Table 13.6 Comparison of Key Factors for the Selection of Contract Service Providers: Harvey Ball Analysis
Table 14.1 List of Companies Using Big Data for Microbiome Research
Table 14.2 Human Longevity: Partnerships and Collaborations
Table 14.3 Human Longevity: Venture Capital Funding
Table 14.4 Resilient Biotics: Venture Capital Funding
Table 15.1 Potential of Key Therapeutic Areas: Estimated Market Growth Rate
Table 15.2 Potential of Key Therapeutic Areas: Estimated Penetration (by 2030)
Table 15.3 Microbiome Therapeutics: Promising Drug Candidates
Table 15.4 Microbiome Therapeutics Forecast Assumptions: Price Estimations in Key Geographies
Table 15.5 IBP-9414 (Infant Bacterial Therapeutics): Net Present Value (USD Million)
Table 15.6 IBP-9414 (Infant Bacterial Therapeutics): Value Creation Analysis (USD Million)
Table 15.7 Oxabact® (OxThera): Net Present Value (USD Million)
Table 15.8 Oxabact® (OxThera): Value Creation Analysis (USD Million)
Table 15.9 RBX2660 (Rebiotix): Net Present Value (USD Million)
Table 15.10 RBX2660 (Rebiotix): Value Creation Analysis (USD Million)
Table 15.11 RP-G28 (Ritter Pharmaceuticals): Net Present Value (USD Million)
Table 15.12 RP-G28 (Ritter Pharmaceuticals): Value Creation Analysis (USD Million)
Table 15.13 SER-109 (Seres Therapeutics): Net Present Value (USD Million)
Table 15.14 SER-109 (Seres Therapeutics): Value Creation Analysis (USD Million)
Table 16.1 Microbiome Diagnostics Forecast Assumptions: Price Estimations in Key Geographies
Table 18.1 List of Companies Engaged in the Development of Microbiome Products for Other Applications
Table 18.2 Pipeline of Microbiome Based Consumer Products, Medical Foods and Supplements
Table 20.1 Floragraph: Company / Organization Snapshot
Table 20.2 S-Biomedic: Company / Organization Snapshot
Table 20.3 Whole Biome: Company / Organization Snapshot
Table 20.4 Siolta Therapeutics: Company / Organization Snapshot
Table 20.5 Assembly Biosciences: Company / Organization Snapshot
Table 20.6 List Biological Laboratories: Company / Organization Snapshot
Table 20.7 Metabiomics: Company / Organization Snapshot
Table 20.8 Microbiome Therapeutics: Company / Organization Snapshot
Table 20.9 Universal Stabilization Technologies: Company / Organization Snapshot
Table 20.10 BiomX: Company / Organization Snapshot
Table 20.11 Da Volterra: Company / Organization Snapshot
Table 20.12 Chung Mei Pharmaceutical: Company / Organization Snapshot
Table 20.13 Pacific Northwest National Laboratories: Company / Organization Snapshot
Table 21.1 Microbiome Therapeutics Clinical Pipeline: Distribution by Phase of Development
Table 21.2 Microbiome Therapeutics Clinical Pipeline: Distribution by Type of Molecule
Table 21.3 Microbiome Therapeutics Clinical Pipeline: Distribution by Type of Therapy
Table 21.4 Microbiome Therapeutics Clinical Pipeline: Distribution by Target Indication
Table 21.5 Microbiome Therapeutics Clinical Pipeline: Distribution by Therapeutic Area
Table 21.6 Microbiome Therapeutics Clinical Pipeline: Distribution by Dosing Frequency
Table 21.7 Microbiome Therapeutics Clinical Pipeline: Distribution by Route of Administration
Table 21.8 Microbiome Therapeutics Clinical Pipeline: Distribution by Drug Formulation
Table 21.9 Microbiome Therapeutics Preclinical Pipeline: Distribution by Phase of Development
Table 21.10 Microbiome Therapeutics Preclinical Pipeline: Distribution by Type of Molecule
Table 21.11 Microbiome Therapeutics Preclinical Pipeline: Distribution by Type of Therapy
Table 21.12 Microbiome Therapeutics Preclinical Pipeline: Distribution by Target Indication
Table 21.13 Microbiome Therapeutics Preclinical Pipeline: Distribution by Therapeutic Area
Table 21.14 Microbiome Therapeutic Developers: Distribution by Year of Establishment
Table 21.15 Microbiome Therapeutic Developers: Distribution by Location of Headquarters
Table 21.16 Microbiome Therapeutic Developers: Distribution by Company Size
Table 21.17 Microbiome Therapeutic Developers: Distribution by Company Size and Location of Headquarters
Table 21.18 Microbiome Therapeutic Developers: Leading Drug Developers
Table 21.19 Ferring Pharmaceuticals: Annual Revenues, 2014-2018 (DKK Million)
Table 21.20 Seres Therapeutics: Annual Revenues, 2016-H1 2019 (USD Million)
Table 21.21 Microbiome Diagnostics: Distribution by Stage of Development
Table 21.22 Microbiome Diagnostics: Distribution by Type of Sample Required
Table 21.23 Microbiome Diagnostics: Distribution by Target Indication
Table 21.24 Microbiome Diagnostics: Distribution by Therapeutic Area
Table 21.25 Microbiome Diagnostics: Distribution by Purpose
Table 21.26 Microbiome Diagnostics Developers: Distribution by Year of Establishment
Table 21.27 Microbiome Diagnostics Developers: Distribution by Location of Headquarters
Table 21.28 Microbiome Diagnostics Developers: Distribution by Company Size
Table 21.29 Microbiome Diagnostics Developers: Distribution by Company Size and Location of Headquarters
Table 21.30 Microbiome Diagnostics Developers: Leading Diagnostic Developers
Table 21.31 FMT: Distribution by Phase of Development
Table 21.32 FMT: Distribution by Therapeutic Area
Table 21.33 FMT: Distribution by Route of Administration
Table 21.34 FMT Developers: Distribution by Year of Establishment
Table 21.35 FMT Developers: Distribution by Location of Headquarters
Table 21.36 FMT Developers: Distribution by Company Size
Table 21.37 Clinical Trial Analysis: Cumulative Distribution of Number of Trials by Registration Year, 2011-2019
Table 21.38 Clinical Trial Analysis: Distribution by Trial Status
Table 21.39 Clinical Trial Analysis: Distribution by Phase of Development
Table 21.40 Clinical Trial Analysis: Distribution by Patients Enrolled
Table 21.41 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2011-2019
Table 21.42 Clinical Trial Analysis: Distribution by Popular Target Indications
Table 21.43 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 21.44 Clinical Trial Analysis: Distribution by Recruitment Status and Trial Registration Year
Table 21.45 Clinical Trial Analysis: Distribution by Study Design
Table 21.46 Clinical Trial Analysis: Leading Non-Industry Players in Terms of Number of Trials Conducted
Table 21.47 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Table 21.48 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 21.49 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 21.50 Diabetes: Diagnostic Limits for Plasma Glucose Levels
Table 21.51 Obese Population: Distribution by Key Regions
Table 21.52 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment
Table 21.53 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2013-2019
Table 21.54 Funding and Investment Analysis: Distribution by Type of Funding and Year of Investment, 2013-2019
Table 21.55 Funding and Investment Analysis: Cumulative Amount Invested, 2013-2019 (USD Million)
Table 21.56 Funding and Investment Analysis: Year-Wise Distribution by Amount Invested and Type of Funding, 2013-2019 (USD Million)
Table 21.57 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2013-2019
Table 21.58 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2013-2019 (USD Million)
Table 21.59 Funding and Investment Analysis: Summary of Amount Invested, 2013-2019 (USD Million)
Table 21.60 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Company, 2013-2019 (USD Million)
Table 21.61 Funding and Investment Analysis: Distribution of the Total Amount Invested by Purpose of Funding, 2013-2019 (USD Million)
Table 21.62 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Product, 2013-2019 (USD Million)
Table 21.63 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Product and Funding Type, 2013-2019 (USD Million)
Table 21.64 Funding and Investment Analysis: Distribution by Therapeutic Area
Table 21.65 Funding and Investment Analysis: Distribution of the Total Amount Invested by Therapeutic Area, 2013-2019 (USD Million)
Table 21.66 Funding and Investment Analysis: Distribution by Target Indication
Table 21.67 Funding and Investment Analysis: Distribution of the Total Amount Invested by Target Indication, 2013-2019 (USD Million)
Table 21.68 Funding and Investment Analysis: Distribution by Geography
Table 21.69 Funding and Investment Analysis: Regional Distribution of Funding Instances
Table 21.70 Funding and Investment Analysis: Most Active Players by Number of Instances and Amount Invested, 2013-2019 (USD Million)
Table 21.71 Funding and Investment Analysis: Most Active Investors by Number of Instances
Table 21.72 Funding and Investment Analysis: Distribution by Type of Investors
Table 21.73 Funding and Investment Analysis: Distribution by Location of Investors
Table 21.74. Survey Respondents (December 2018): Distribution by Respondent Particular
Table 21.75. Microbiome Therapeutics: Distribution by Manufacturing Preference
Table 21.76. Survey Respondents (June 2019): Distribution by Respondent Particulars
Table 21.77. Microbiome Therapeutics: Distribution by Most Popular Analytical Techniques
Table 21.78. Overall Microbiome Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.79. Microbiome Therapeutics Market: Distribution by Type of Therapy, 2025 and 2030
Table 21.80. Microbiome Therapeutics Market for Prescription Drugs, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.81. Microbiome Therapeutics Market for Prebiotic Drugs, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.82. Microbiome Therapeutics Market for Probiotic Drugs, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.83. Microbiome Therapeutics Market: Distribution by Type of Molecule, 2025 and 2030
Table 21.84. Microbiome Therapeutics Market for Small Molecules, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.85. Microbiome Therapeutics Market for Biologics, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.86. Microbiome Therapeutics Market: Distribution by Target Indication, 2025 and 2030
Table 21.87. Microbiome Therapeutics Market for Acne Vulgaris, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.88. Microbiome Therapeutics Market for Atopic Dermatitis, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.89. Microbiome Therapeutics Market for Recurrent Bacterial Vaginosis, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.90. Microbiome Therapeutics Market for CDI, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.91. Microbiome Therapeutics Market for Crohn’s Disease, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.92. Microbiome Therapeutics Market for Dental Caries, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.93. Microbiome Therapeutics Market for Diabetes, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.94. Microbiome Therapeutics Market for IBS, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.95. Microbiome Therapeutics Market for Lactose Intolerance, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.96. Microbiome Therapeutics Market for Lung Cancer, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.97. Microbiome Therapeutics Market for Malignant Melanoma, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.98. Microbiome Therapeutics Market for NASH, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.99. Microbiome Therapeutics Market for NEC, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.100. Microbiome Therapeutics Market for Primary Hyperoxaluria, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.101. Microbiome Therapeutics Market for Psoriasis, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.102. Microbiome Therapeutics Market for Ulcerative Colitis, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.103. Microbiome Therapeutics Market for UTI, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.104. Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2025 and 2030
Table 21.105. Microbiome Therapeutics Market for Autoimmune Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.106. Microbiome Therapeutics Market for Dental Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.107. Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.108. Microbiome Therapeutics Market for Dermatological Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.109. Microbiome Therapeutics Market for Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.110. Microbiome Therapeutics Market for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.111. Microbiome Therapeutics Market for Oncology, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.112. Microbiome Therapeutics Market: Distribution by Key Geographical Regions, 2025 and 2030
Table 21.113. Microbiome Therapeutics Market in North America, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.114. Microbiome Therapeutics Market in Europe, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.115. Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.116. Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2025 and 2030 (USD Million)
Table 21.117. Microbiome Therapeutics Market: Distribution by Leading Drugs, 2019-2030 (USD Million)
Table 21.118. IBP-9414 (Infant Bacterial Therapeutics): Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 21.119. Oxabact (OxThera): Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 21.120. RBX2660 (Rebiotix): Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 21.121. RP-G28 (Ritter Pharmaceuticals): Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 21.122. SER 109 (Seres Therapeutics): Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 21.123. Overall Microbiome Diagnostics Market, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.124. Microbiome Diagnostics Market: Distribution by Target Indications, 2019-2030 (USD Million)
Table 21.125. Microbiome Diagnostics Market for Colorectal Cancer, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.126. Microbiome Diagnostics Market for Diabetes, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.127. Microbiome Diagnostics Market for IBD, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.128. Microbiome Diagnostics Market for IBS, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.129. Microbiome Diagnostics Market for NASH, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.130. Microbiome Diagnostics Market for Obesity, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.131. Microbiome Diagnostics Market for Others, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.132. Overall Microbiome Diagnostics Market, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.133. Microbiome Diagnostics Market: Distribution by Target Indications, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.134. Microbiome Diagnostics Market for Colorectal Cancer, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.135. Microbiome Diagnostics Market for IBD, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.136. Microbiome Diagnostics Market for Diabetes, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.137. Microbiome Diagnostics Market for IBS, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.138. Microbiome Diagnostics Market for NASH, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.139. Microbiome Diagnostics Market for Obesity, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.140. Microbiome Diagnostics Market: Distribution by Therapeutic Areas, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.141. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.142. Microbiome Diagnostics Market for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.143. Microbiome Diagnostics Market for Oncology, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.144. Microbiome Diagnostics Market for Others, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD, Million)
Table 21.145. Microbiome Diagnostics Market: Distribution by Therapeutic Areas, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.146. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.147. Microbiome Diagnostics Market for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.148. Microbiome Diagnostics Market for Oncology, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.149. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.150. Microbiome Diagnostics Market in North America, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.151. Microbiome Diagnostics Market in Europe, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.152. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.153. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.154. Microbiome Diagnostics Market in North America, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.155. Microbiome Diagnostics Market in Europe, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.156. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.157. Overall FMT Market, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.158. Overall FMT Market, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.159. Overall Microbiome Market by Product Offerings, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 16S Technologies
  2. 4D Pharma 
  3. 5QBD-Biotech
  4. Aalborg University Hospital
  5. Aarhus University
  6. AB-Biotics
  7. Abbott Laboratories
  8. AbbVie
  9. Abraxis BioScience
  10. Academic Medical Centre (Amsterdam UMC)
  11. ActoBio Therapeutics
  12. Adapsyn Bioscience
  13. Adare Pharmaceuticals
  14. AdvancingBio
  15. AEProbio
  16. Aetna
  17. AgBiome
  18. Ajuvis Labsd
  19. Alaven Pharmaceutical
  20. Aleris-Hamlet Hospital 
  21. Alimentary Health (Part of PrecisionBiotics Group)
  22. Alimentary Pharmabiotic Centre Microbiome Institute, University College Cork (UCC)
  23. Allergan
  24. Allergy Therapeutics
  25. Altis Biosystems
  26. Amabiotics 
  27. Amazon
  28. American College of Gastroenterology
  29. Ample
  30. AmpliPhi Biosciences 
  31. Amrita Therapeutics
  32. Anavex Life Sciences
  33. AnimalBiome
  34. ANIZOME
  35. AOBiome Therapeutics 
  36. Ardigen
  37. Arena Pharmaceuticals
  38. Arizona State University
  39. Armata Pharmaceuticals
  40. Artizan Biosciences
  41. ARTPred
  42. Ascus Biosciences
  43. Asia Microbiota Bank
  44. AsiaBiome (formely known as Civet Biosciences)
  45. Assaf Harofeh Medical Center
  46. Assembly Biosciences
  47. APHM (Public Assistance - Marseille Hospitals)
  48. APHP (Public Assistance - Paris Hospitals)
  49. Astarte Medical 
  50. Astel Medica
  51. AstraZeneca
  52. Atlas Biomed
  53. Autonomous University of Nuevo León
  54. Aventis Pharma
  55. AvidBiotics
  56. Axcan Pharma
  57. Axial Biotherapeutics
  58. Azitra
  59. Bactana
  60. Bayer
  61. Baylor College of Medicine
  62. Becton Dickinson 
  63. Beiersdorf
  64. Beth Israel Deaconess Medical Center
  65. Bio Farma
  66. Biocartis 
  67. Biocodex
  68. BioControl (Acquired by Merck)
  69. BioGaia
  70. Biogen
  71. Biohit Healthcare
  72. BIOHM Health
  73. Bio-K Plus International
  74. Biom Pharmaceuticals
  75. BioMathematica 
  76. BiomCare
  77. Bio-Me
  78. Biome Makers
  79. Biome360
  80. BiomeBliss
  81. Biomecite Diagnostics
  82. BiomeSense
  83. Biomica (subsidiary of Evogene)
  84. Biomillenia
  85. BiomX
  86. BioRankings
  87. Biorasi
  88. biose
  89. Biotagenics
  90. Blis Probiotics
  91. Blue Biology
  92. Blue Turtle Bio 
  93. Boehringer Ingelheim
  94. BoobyBiome
  95. Boston Children’s Hospital
  96. Boston Medical Center
  97. Brigham and Women's Hospital
  98. Bristol-Myers Squibb
  99. BugSpeak
  100. Caelus Health
  101. California Institute of Technology (Caltech)
  102. Campus Bio-Medico University
  103. Canadian Association of Gastroenterology
  104. Canadian Institutes of Health Research 
  105. Capsugel
  106. Captozyme
  107. Carbiotix
  108. CARB-X
  109. Careggi University Hospital
  110. Case Comprehensive Cancer Center
  111. Catholic University of the Sacred Heart
  112. Cedars-Sinai Medical Center
  113. Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology
  114. Center of Food and Fermentation Technologies
  115. Centers for Disease Control and Prevention
  116. CHAIN Biotechnology
  117. Charles River Laboratories
  118. Children's Hospital Los Angeles
  119. Children's Hospital of Philadelphia
  120. Children's Mercy Hospital Kansas City
  121. Chr. Hansen
  122. Chugai Pharmaceutical
  123. Chung Mei Pharmaceutical
  124. ChunLab
  125. Cigna
  126. CIPAC Healthcare
  127. Clasado BioSciences
  128. ClearB Therapeutics
  129. Clinical Investigation Center for Innovative Technology Network 
  130. Clinical Microbiomics
  131. ClostraBio
  132. Cobra Biologics
  133. Commense (a subsidiary of PureTech Health)
  134. Concentric Ag
  135. Cook MyoSite
  136. CoreBiome
  137. Cornell University
  138. CosmosID
  139. Covaris
  140. CRB-HUEP
  141. Crohn's & Colitis Foundation
  142. CRS Bio
  143. Cykinso
  144. Dairy & Food Culture Technologies 
  145. Dakota BioTech
  146. Danisco
  147. Da Volterra
  148. Dayanand Medical College & Hospital
  149. DayTwo
  150. DermBiont
  151. Diagnostic Solutions Laboratory
  152. Diversigen
  153. DNA Genotek
  154. Duke University
  155. DuPont
  156. Eagle Genomics
  157. Eat Troo
  158. Eatrics
  159. Edico Genome (Acquired by Illumina)
  160. EirGenix
  161. Eli Lilly
  162. ELiE Health Solutions
  163. Embion Technologies
  164. EmblemHealth
  165. Emory University
  166. Emulate
  167. Englewood Health
  168. Enterin
  169. EnteroBiotix
  170. Enterome Bioscience
  171. EpiBiome (Acquired by Locus Biosciences)
  172. Esse Skincare
  173. European Commission
  174. European Society of Clinical Microbiology and Infectious Diseases 
  175. Evelo Biosciences
  176. Evolve BioSystems
  177. Evotec
  178. EXDEN
  179. Exeliom Biosciences (formerly known as Nextbiotix)
  180. EzBioCloud
  181. Fecal Microbiota Transplantation Workgroup
  182. Federal Research and Clinical Center of Physical-Chemical Medicine
  183. FermBiotics
  184. Ferring Pharmaceuticals
  185. Finch Therapeutics
  186. First Affiliated Hospital of Chengdu Medical College
  187. Flora Medicine
  188. Floragraph
  189. First Affiliated Hospital of Nanchang University
  190. Fortify
  191. Foundation of Hope
  192. Fourth Military Medical University
  193. Frontier Science & Technology Research Foundation
  194. FUJIFILM Diosynth Biotechnologies
  195. Fuzhou General Hospital
  196. G.D Searle
  197. Galderma
  198. Gallinée
  199. GALT
  200. Genetic Analysis
  201. Institute of Molecular Genetics Academy of Sciences Czech Republic 
  202. GENEWIZ
  203. Genome and Company
  204. Genova Diagnostics
  205. Genten Therapeutics
  206. German Federal Ministry of Education and Research
  207. Ghent University
  208. GI Innovation
  209. Ginkgo Bioworks
  210. Global Cosmetics 
  211. GNUbiotics Sciences
  212. GoodBelly
  213. GoodGut
  214. Groken Bioscience
  215. GlaxoSmithKline 
  216. GT Biologics
  217. Guangzhou First People's Hospital
  218. Gülhane Institute of Health Sciences 
  219. Gusto Global
  220. Hadassah Medical Center
  221. Hamilton Health Sciences
  222. Harvest Capital Strategies
  223. Haukeland University Hospital
  224. Health Net
  225. HealthPartners
  226. University of Helsinki 
  227. Hoechst Marion Roussel
  228. Holobiome
  229. Hospital District of Helsinki and Uusimaa
  230. Hospital for Sick Children
  231. Hospital Ramón y Cajal
  232. Hudson Institute of Medical Research 
  233. Human Longevity
  234. Hunter Holmes McGuire Veterans Administration Medical Center 
  235. Hvidovre Hospital
  236. Hy Laboratories
  237. Hyggut
  238. IBM
  239. Icahn School of Medicine at Mount Sinai
  240. iCarbonX
  241. Igen Biolab Group 
  242. ImClone Systems
  243. ImmuneBiotech
  244. Immunex
  245. Immuron
  246. Indiana University
  247. Indigo Therapeutics
  248. Inserm
  249. Institut Allergosan
  250. Institut national de la recherche agronomique 
  251. Institute for Clinical and Experimental Medicine
  252. The Institute of Animal Physiology
  253. Institute of Liver and Biliary Sciences
  254. Intralytix
  255. Intrexon
  256. Intuition Biosciences
  257. Invivo Healthcare
  258. Ipsat Therapies
  259. Ironwood Pharmaceuticals
  260. IS-Diagnostics
  261. Island Health
  262. Isohelix
  263. ISOThrive
  264. Ixcela
  265. Ixion Biotechnology
  266. J. Craig Venter Institute
  267. Janssen Biotech
  268. Jena University Hospital
  269. Jinling Hospital
  270. John Theurer Cancer Center
  271. Johnson & Johnson
  272. Joint Authority for Päijät-Häme Social and Health Care
  273. Juno Bio
  274. Kaleido Biosciences
  275. Kallyope
  276. Karolinska Institutet
  277. Kelsey Research Foundation
  278. Keystone Bio
  279. King's College London
  280. Kingston Health Sciences Centre
  281. Kintai Therapeutics
  282. KNOMICS MICROBIOTA
  283. Kobiolabs
  284. La Trobe University
  285. Laboratorio Cobas
  286. Lactobio
  287. Lallemand Health Solutions
  288. Lavie Bio
  289. Lawrence Berkeley National Laboratory
  290. Lawson Health Research Institute
  291. Leadiant Biosciences 
  292. Leiden University
  293. Lesaffre Human Care
  294. Levanger Hospital
  295. List Biological Laboratories
  296. LNC Therapeutics
  297. Locus Biosciences
  298. London Health Sciences Centre
  299. Lonza 
  300. Lovisenberg Diakonale Hospital
  301. LUCA Biologics
  302. Luina Bio
  303. Luxia Scientific
  304. M.D. Anderson Cancer Center
  305. MaaT Pharma
  306. Madison University
  307. Maiden Therapeutics
  308. Mankind Pharma
  309. Manufacturer Vilhelm Pedersen Foundation
  310. Marqués de Valdecilla University Hospital
  311. Masonic Cancer Center
  312. Massachusetts General Hospital
  313. Massachusetts Institute of Technology
  314. MatriSys Bioscience
  315. Mayo Clinic
  316. McMaster University
  317. MD Anderson Cancer Center
  318. Medeva Pharmaceuticals
  319. Medical College of Wisconsin
  320. Medical University of Graz
  321. Medlab
  322. Memorial Medical Center Foundation
  323. Memorial Sloan Kettering Cancer Center
  324. Memorial University of Newfoundland
  325. MemorialCare Health System
  326. Merck
  327. Merge Healthcare
  328. Metabiomics
  329. MetaboGen
  330. Michael E. DeBakey Veterans Affairs Medical Center
  331. Mitchell Cancer Institute 
  332. Microba
  333. Microbiome Diagnostic Partners
  334. Microbiome Health Research Institute
  335. Microbiome Insights
  336. Microbiome Research Centre
  337. MicroBiome Therapeutics
  338. Microbiome Therapeutics Innovation Group
  339. MicrobiomeDx
  340. Microbiotica
  341. Microinventa
  342. Microsoft
  343. Microviable Therapeutics
  344. Millennium Pharmaceuticals
  345. Miomics
  346. Miyarisan Pharmaceutical
  347. Modena University Hospital
  348. Molzym
  349. Monash University
  350. Montefiore Medical Center
  351. Moon Biotech
  352. Mount Sinai Hospital
  353. mybacs
  354. MyBiotics
  355. MyMicroZoo
  356. NAFLD Research Center, University of California San Diego School of Medicine
  357. Naked Biome
  358. Nantes University Hospital
  359. National Cancer Institute (NCI)
  360. The National Institute for Health and Care Excellence (NICE)
  361. National Institute of Allergy and Infectious Diseases (NIAID)
  362. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  363. National Institute for Health and Medical Research (INSERM)
  364. National Institutes of Health (NIH)
  365. National Jewish Health
  366. National PKU Alliance
  367. Nationwide Children's Hospital
  368. Nestlé Health Science
  369. New York University
  370. New Zealand Society of Gastroenterology
  371. NIZO
  372. Nordland Hospital Trust
  373. NorthShore University HealthSystem
  374. Norway Regional Health Authority
  375. Norwegian University of Science and Technology
  376. Novartis
  377. Novo Nordisk
  378. Novogene
  379. Novome Biotechnologies
  380. Nubiyota
  381. Open Patient data Explorative Network
  382. Odense University Hospital
  383. Ohio State University Wexner Medical Center
  384. Omega Biomics
  385. One Codex 
  386. OpenBiome
  387. OptiBiotix
  388. Oragenics
  389. Oralta
  390. Orebro University
  391. Oregon State University 
  392. Orexigen Therapeutics
  393. Osel
  394. OSI Pharmaceuticals
  395. Oslo University Hospital
  396. OxThera
  397. Pacific Northwest National Laboratory (PNNL)
  398. Paragon Bioservices (unit of Catalent Biologics)
  399. Parker Institute for Cancer Immunotherapy
  400. Vlaamse Parkinson Liga
  401. Parkinson's Institute and Clinical Center
  402. Peking Union Medical College Hospital
  403. Pendulum Therapeutics (formerly known as Whole Biome)
  404. Perrigo 
  405. Persona Biome
  406. Pfizer
  407. Pharmacia & Upjohn 
  408. Pharm-Olam 
  409. Phase Genomics
  410. Phi Therapeutics
  411. Phylagen
  412. Pierre and Marie Curie University
  413. Pierre Fabre 
  414. Pillar Healthcare
  415. Postbiotics Plus
  416. Postgraduate Institute of Medical Education and Research
  417. PrecisionBiotics
  418. Presutti Laboratories
  419. Prime Discoveries
  420. Priority Health
  421. Probiotical
  422. ProdermIQ
  423. ProDigest
  424. Prometheus Laboratories
  425. PSI Foundation
  426. Psoriasis Association
  427. Psychiatric Hospital of the University of Basel
  428. Public Health England
  429. Public Health Ontario 
  430. Puerta de Hierro University Hospital
  431. Qiara 
  432. Qingdao Institute of Bioenergy and Bioprocess Technology 
  433. Quadram Institute 
  434. Quay Pharma
  435. Queen Elizabeth II Health Sciences Centre
  436. Queen's University
  437. Quorum Innovations
  438. Quotient Sciences
  439. Rambam Healthcare Campus
  440. Rebiotix (part of Ferring Pharmaceuticals Group)
  441. Regence BlueShield
  442. Regeneron Pharmaceuticals
  443. Replete Biotics
  444. Research Foundation - Flanders
  445. Research Institute of St Joe’s Hamilton
  446. Resilient Biotics
  447. Resphera Biosciences
  448. Rise Therapeutics
  449. Ritter Pharmaceuticals
  450. Roche
  451. RondinX (Acquired by BiomX)
  452. Roswell Park Comprehensive Cancer Center
  453. Ruprecht Karl University of Heidelberg
  454. Rush University
  455. Sabinsa 
  456. Saint-Antoine Hospital
  457. Salix Pharmaceuticals
  458. Sanofi
  459. S-Biomedic
  460. Scaled Microbiomics
  461. SciBac
  462. Scioto Biosciences
  463. Seattle Children's Hospital
  464. Second Genome
  465. Seed Health
  466. Santa Maria della Misericordia Hospital
  467. Seres Therapeutics
  468. SFA Therapeutics
  469. Shanghai Children's Medical Center
  470. Shanghai General Hospital
  471. Shanghai Jiao Tong University School of Medicine
  472. Shanghai Zhongshan Hospital
  473. Sheba Medical Center
  474. Shoreline Biome
  475. Sicor
  476. Siffra Farmaceutici
  477. Sinai Health System
  478. Siolta Therapeutics
  479. Sjogren’s Syndrome Foundation
  480. SkinBioTherapeutics
  481. Snipr Biome
  482. Solarea Bio
  483. Soroka Medical Center
  484. SRZ Properties
  485. St. Justine's Hospital
  486. Stanford Cancer Institute
  487. Stanford University School of Medicine
  488. Stony Brook University
  489. Sucampo Pharmaceuticals
  490. Sugarlogix
  491. Sun Genomics
  492. Symberix
  493. Symbiota
  494. Symbiotix Biotherapies
  495. Syneos Health
  496. Synergy Worldwide
  497. Synlogic
  498. Synthetic Biologics
  499. Synthetic Genomics 
  500. Taiho Pharmaceutical
  501. Takeda Pharmaceutical 
  502. TargEDys
  503. Tel Aviv Sourasky Medical Center
  504. Temple University
  505. Teva Pharmaceutical
  506. Texas Digestive Diseases Center
  507. Texas Children’s Hospital 
  508. The BioCollective
  509. The Chinese University of Hong Kong
  510. The Danish Rheumatism Association
  511. The Flanders Institute for Biotechnology
  512. The Jackson Laboratory
  513. The Miriam Hospital
  514. The Research Council of Norway
  515. The Second Affiliated Hospital of Nanjing Medical University
  516. The University of Texas Health Science Center
  517. The University of Texas MD Anderson Cancer Center
  518. The Weston A Price Foundation
  519. Thryve Digital
  520. Tongji Hospital
  521. Toronto Invasive Bacterial Diseases Network
  522. Tortuga Biosciences
  523. Trayer Biotherapeutics
  524. Triphase Pharmaceuticals
  525. TULA Skincare
  526. uBioDiscovery
  527. uBiome
  528. UCB Pharma
  529. Umeå University
  530. Universitair Ziekenhuis Leuven
  531. University Health Network
  532. University Hospital Cologne
  533. University Hospital of Limoges
  534. University Hospital of North Norway
  535. University of Adelaide
  536. University of Alberta
  537. University of British Columbia
  538. University of Calgary
  539. University of California
  540. University of Chicago
  541. University of Chieti
  542. University of Florence
  543. University of Maryland 
  544. University of Massachusetts
  545. University of Melbourne
  546. University of Miami
  547. University of Minnesota
  548. University of Modena and Reggio Emilia
  549. University of New South Wales
  550. University of North Carolina
  551. University of North Texas
  552. University of Oslo
  553. University of Pennsylvania
  554. University of Pittsburgh
  555. University of Portsmouth
  556. University of Southern Denmark
  557. University of Surrey
  558. University of Texas
  559. University of Toronto
  560. University of Tromso
  561. University of Vermont
  562. University of Wisconsin
  563. University of Zurich
  564. US Army Medical Research and Materiel Command
  565. US Department of Veterans Affairs
  566. VA Office of Research and Development
  567. Vaiomer
  568. Vancouver General Hospital
  569. Varinos
  570. Vast Biome
  571. Vedanta Biosciences 
  572. Vertex Pharmaceuticals
  573. Viome
  574. Virginia Commonwealth University
  575. Visbiome
  576. ViThera Pharmaceuticals
  577. Vitrilife
  578. Vivus
  579. WACKER (formerly known as Synco Bio)
  580. Washington University School of Medicine
  581. Weill Cornell Medical College of Cornell University
  582. Wellmicro 
  583. Western Sydney Local Health District 
  584. Westmead Institute for Medical Research
  585. Winclove Probiotics
  586. Wolfson Medical Center
  587. Women's College Hospital
  588. Xbiome
  589. Xycrobe Therapeutics
  590. Yakult Honsha
  591. Yonsei University
  592. Zehna Therapeutics
  593. ZMD Group

Segmentation

Over USD 4 billion (by 2030) financial opportunity within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has been analyzed across the following segments:

Type of Therapy (Tx)

  • Prescription Drug
  • Prebiotics
  • Probiotics

Type of Molecule (Tx)

  • Small Molecules
  • Biologics

Target Indication (Tx+Dx)

  • Acne Vulgaris
  • Atopic Dermatitis
  • Clostridium difficile Infection
  • Colorectal Cancer
  • Crohn’s Disease
  • Diabetes
  • Irritable Bowel Syndrome
  • Lactose Intolerance
  • Lung Cancer
  • Nonalcoholic steatohepatitis (NASH)
  • Obesity
  • Ulcerative colitis

Therapeutic Area (Tx+Dx)

  • Autoimmune Disorders
  • Dental Disorders
  • Digestive and Gastrointestinal Disorders
  • Dermatological Disorders
  • Infectious Disease
  • Metabolic Disorders
  • Oncology
  • Others

Supply Channel (Tx+Dx)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Key Geographical Regions (Tx+Dx)

  • North America
  • Europe
  • Asia-Pacific and Rest of the World

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com